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Harm reduction interventions for people who use 
drugs—such as needle and syringe programmes 
(NSP) and opioid substitution therapy (OST)—are 
cost-effective, protect against HIV and hepatitis 
C, and save lives. Despite the potential for 
these interventions to contribute to healthier 
communities, funding for harm reduction in low- 
and middle-income countries (LMICs) has flat-lined 
over the past decade. In 2016, US$188 million was 
allocated – the same amount as in 2007 and just 
13% of the US$1.5 billion that UNAIDS estimates  
is required for an effective response in LMICs.
Beneath this enormous funding shortfall are 
disturbing trends. International donor funding, 
which comprises the majority of harm reduction 
funding in LMICs, is declining. Donor governments 
are withdrawing direct funding to countries 
for harm reduction on the basis that it is being 
channelled through multilateral institutions like 
the Global Fund to Fight AIDS, Tuberculosis and 
Malaria (Global Fund). Yet, Global Fund support 
for harm reduction may be decreasing, with data 
suggesting allocations in 2016 are 18% lower than 
those in 2011. Simply put, the lives of people who 
use drugs are being neglected.
The consequences of this donor retreat cannot  
be overstated. People who inject drugs are among 
the most vulnerable to contracting blood-borne 
viruses. New HIV infections among this population 
increased by one third from 2011-15, and HIV 
epidemics among people who inject drugs are 
commonplace in Asia and Eastern Europe. Harm 
reduction is integral to the world’s HIV response 
and cannot be ignored. This is particularly true 
in upper-middle income countries where the 
majority of the world’s 11 million people who 
inject drugs live.
In the face of donor withdrawal for harm 
reduction the onus is shifting to national 
governments. There are select bright spots where 
LMIC governments are working to protect people 
who use drugs through a scale-up in funding.  
But more needs to be done and, in environments 
where people who use drugs are criminalised and 
excluded, these gains are fragile at best. As Harm 
Reduction International’s research has detailed 
in the past, an initial step to meet the funding 
needs would be redirecting a small portion of the 
considerable resources spent on drug control 
to harm reduction interventions. Our modelling 
shows that a 7.5% shift in resources could bring 
about a 94% drop in new HIV infections among 
people who inject drugs by 2030. 
This is not to say that international donors  
can wash their hands of the issue. Collectively, 
they must increase their support for harm 
reduction – particularly for priority interventions 
like NSP and OST – to fill the sizeable funding gap. 
Any transition from international to domestic 
funding has to be gradual with a concrete plan 
in place to ensure that donor withdrawal doesn’t 
result in the cut off of harm reduction services. 
It is important to acknowledge that because 
a majority of international donor funding for 
harm reduction comes from the HIV sector, this 
report necessarily tackles select harm reduction 
interventions focused on injecting drug use. 
In reality, harm reduction is far broader than 
In Harm Reduction International’s 2010 report on the state of global funding for 
harm reduction, we stressed, ‘more money is needed for harm reduction, and it  
is needed now’. Sadly, this statement remains true in 2018. 
Harm reduction is integral to the 
world’s HIV response and cannot  
be ignored. 
Acronyms and Abbreviations
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this. It covers a range of substances, overdose 
prevention, and wider healthcare and social 
interventions for people who use drugs. 
Fundamentally, it is about meeting people  
where they are at in their lives without judgement. 
When governments invest in this strategy beyond 
the lens of HIV prevention, the public health  
and social impact for individuals, families  
and communities will be significant. 
With the global HIV response now operating 
against the backdrop of the 2015 Sustainable 
Development Goals (SDGs), including the aim to 
end AIDS by 2030 and ‘leave no one behind’, the 
expectation has never been so great. Unless the 
funding landscape for harm reduction changes 
urgently, this goal will come and go as others have 
and the pledge to leave no one behind will ring 
hollow. People who use drugs are being forgotten 
- with dire public health and social consequences. 
This report demands donors act urgently to 
address the lost decade in funding for harm 
reduction and prevent an escalation of the  
current health crisis. 
Recommendations:
The below are high-level recommendations  
from the report. More detailed recommendations 
for international donors and governments are 
included throughout.
l  International donors must increase harm 
reduction funding in line with epidemiological 
need and not withdraw or reduce funds without 
adequate transition plans in place. 
l  Donor governments must fund harm reduction 
bilaterally and not rely solely on contributions to 
multilaterals and the UN to meet harm reduction 
commitments.
l  Philanthropic donors must increase their 
support for harm reduction, and leverage their 
position as funders to call for other philanthropic, 
national and multilateral donors to increase their 
commitments to harm reduction. 
l  International donors, including donor 
governments, must ensure full replenishment  
for the Global Fund and the Robert Carr civil 
society Networks Fund, and ensure that the  
Joint UN Programme on HIV/AIDS (in particular 
UNODC as the lead agency on HIV and drugs) 
is sufficiently funded to achieve the Fast Track 
Strategy to end AIDS by 2030.
l  The Global Fund should increase its harm 
reduction funding and ensure funds are directed 
to countries with the greatest need, regardless  
of income status. 
l  PEPFAR should increase harm reduction 
funding and ensure funds are used for priority 
interventions, such as needle and syringe 
programmes and opioid substitution therapy. 
l  National governments should invest in their own 
harm reduction responses. They should critically 
evaluate their drug policy spending and redirect 
resources from ineffective drug law enforcement 
to harm reduction.
1. Harm reduction  
funding in low and  
middle income  
countries
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Harm reduction aims to reduce the health, social 
and economic harms associated with drug use, 
without requiring people to stop using drugs.[1] 
It is an approach underpinned by the principles 
of pragmatism, dignity, human rights and public 
health, and one within which people who use 
drugs are firmly at the centre. 
Over the past decade, Harm Reduction 
International (HRI) has documented a slow 
and steady increase in countries adopting 
harm reduction. In 2016, 90 countries were 
implementing needle and syringe programmes 
(NSPs) to some degree and 80 had at least one 
opioid substitution programme (OST) in place.[2] 
However, only one-hundredth of the world’s 
people who inject drugs live in countries where 
these two lifesaving harm reduction measures are 
widely available.[3] In most low and middle income 
countries (LMICs) programmes remain small-
scale and lack the financial and political support 
necessary to meet national need. 
In LMICs, a small number of governments have 
provided domestic support for harm reduction; 
however, the majority of funding has come from 
international donors. Funds have almost always 
been provided from budgets for key population 
programmes as part of the international HIV 
response, with the effect that harm reduction 
interventions not seen as central to addressing 
the HIV epidemic have been neglected, such 
as, overdose prevention, the response to viral 
hepatitis, or harm reduction for non-injecting  
drug use. 
Donor funds have been crucial to turning 
HIV epidemics around in many countries and 
have saved countless lives. Harm reduction 
programmes in countries such as Vietnam 
and Ukraine have been credited with dramatic 
reductions in new HIV infections among people 
who inject drugs. These successes demonstrate 
the potential impact of harm reduction when 
adequately supported and resourced. 
1.  Harm reduction funding in low  
and middle income countries
Throughout this report, we use the phrase ‘people who inject drugs’ where we are referring to 
specific data or circumstances. We otherwise default to the broader, more inclusive framing of 
‘people who use drugs’.
Since 2007 when HRI commenced research on  
this issue, harm reduction funding has fallen 
short of every published estimate of need for 
addressing HIV among people who inject drugs. 
In 2016, it is estimated that US$188 million was 
allocated to harm reduction in LMICs, equating 
to just 13% of the US$1.5 billion that the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) 
estimates is required annually by 2020 for an 
effective response. 
1.2 The current state of harm reduction funding  
in low and middle income countries
In 2016, it is estimated that US$188 
million was allocated to harm 
reduction in LMICs, equating to just 
13% of the estimated US$1.5 billion 
required for an effective response.
1. The estimate included OST and ‘PWID outreach’. 
2. UN guidelines consider coverage of 40% for OST and 60% for NSP to be high.
What resources are needed for harm reduction in low and middle income countries?
In 2011, UNAIDS released the Strategic Investment Framework, which included an annual needs 
estimate of US$2.3 billion for HIV prevention, treatment and care for people who inject drugs in 
LMICs to be achieved by 2015.[4]
In 2015, UNAIDS estimated that US$26.2 billion annual investment was needed by 2020 to  
fund their Fast Track Strategy to End AIDS by 2030.[5] UNAIDS published a resource needs  
estimate of US$1.5 billion annually by 2020 to reach 90% of people who inject drugs with  
harm reduction services1.[6] 
In 2016, Harm Reduction International’s ‘The Case for a Harm Reduction Decade’ report undertook 
mathematical modelling to illustrate the potential of redirecting a small percentage of spending  
on drug control to harm reduction. Redirecting just 7.5% of drug control spending globally  
(US$7.5 billion) would bring high coverage2 for harm reduction. By 2030, the results of this  
would be staggering, enabling us to cut new HIV infections among people who inject drugs  
by 94% and reduce HIV-related death by similar proportions.[7] 
There are differences in the methods and parameters used to reach these estimates of resource 
need. But whichever is used, it is clear that the current level of harm reduction funding is 
desperately low in comparison to estimated need. For each year that we remain so far off target,  
we allow HIV and viral hepatitis epidemics to increase and, as a result, the resources needed to  
end AIDS will also grow. 
1.1 Introduction
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The challenges in estimating harm reduction investment 
Assessing the amount invested in harm reduction is extremely challenging. Information is not 
systematically collected in a way that is conducive to isolating harm reduction spend, or is not 
made public by governments or donors. Funders are often only able to identify allocations  
rather than actual expenditure, which is problematic as these can be quite different. Donors  
and governments use different categories to record funding information, with the result being  
a lack of clarity on the harm reduction activities funded and an inability to meaningfully compare 
spend across providers. 
For this study, Harm Reduction International gathered the best possible data on harm reduction 
investments in LMICs, from a range of sources. In surveying international donors, we attempted  
to capture funds going towards the delivery of the UN-recommended package of interventions,  
as well as related training/capacity building, research and advocacy. We also requested 
geographical and programmatic detail for harm reduction investments and specifically asked 
about funds for neglected areas of harm reduction programming, such as overdose prevention, 
prisons and harm reduction for stimulant use (e.g., amphetamine-type stimulants or cocaine). 
When assessing domestic investment, secondary data was gathered from a range of sources.  
The year of funding information and quality of data gathered varied considerably. 
The great variability in the information gathered means there are numerous caveats and 
limitations attached to the data in this report. These issues highlight the drastic need for 
improvements in accuracy of recording harm reduction investment and ease of access to  
this information. However, even allowing for these caveats, the conclusion that harm reduction  
is dramatically underfunded remains unquestionably clear.
Current high-level goals and commitments related to harm reduction funding
In 2015, world leaders adopted the Sustainable Development Goals (SDGs), which include a target 
to end AIDS and combat hepatitis C by 2030, strengthen the prevention and treatment of drug use, 
and to achieve universal health coverage.  Central to all SDGs is a commitment to ‘leave no one 
behind’.[11] 
Also in 2015, UNAIDS adopted its 2016-2021 Strategy ‘On the Fast Track Strategy to End AIDS’ that 
includes an ambitious set of targets. Most relevant for harm reduction is the target that 90% of 
key populations, including people who inject drugs,3 have access to HIV combination prevention 
services by 2020.[5]
The commitment to end AIDS and achieve Fast-Track targets was reaffirmed by member states 
in the 2016 UN Political Declaration on HIV and AIDS. Most significant for harm reduction was 
the commitment to a 75% reduction in new adult HIV infections to less than 500,000 annually by 
2020. In order to reach the ambitious targets, member states committed to increasing and fully 
funding the AIDS response from all sources, including from innovative financing, and reaching 
overall financial investments in LMICs of at least US$26.2 billion annually by 2020, with a continued 
increase from the current levels of domestic public and private sources.[12] 
Member states also noted with alarm the slow progress in reducing new HIV infections and the 
limited scale of combination prevention programmes, especially among key populations, and 
committed to ensuring that financial resources for prevention are adequate and constitute no  
less than a quarter of AIDS spending globally on average.[12] 
In order to mobilise resources for HIV prevention, UNAIDS, the United Nations Population Fund 
(UNFPA) and partners adopted the HIV Prevention Road Map in October 2017. The Road Map is 
based on five prevention pillars, the second of which is ‘combination prevention programmes 
for all key populations’ and explicitly includes harm reduction services for people who use drugs. 
The Road Map is relevant for all LMICs, but it focuses on 25 countries with high numbers of new 
infections in adolescents and adults in 2016.[13] 
3. The others are: sex workers, men who have sex with men, transgender people, prisoners, and migrants
4. This has been calculated using population size estimates of people who inject drugs and harm reduction funding at a country level and summing for a total 
for low and middle-income countries (LMICs). All LMICs included in this study that had population size estimates were part of the analysis. Size estimations 
were taken from a number of sources; Global State of Harm Reduction (2016 and 2018 pre-published data), Degenhardt et al. and UNODC’s World Drug 
Report. Where an estimate was not available for a country, it was excluded from the analysis.
Perhaps most striking of all is the finding that 
there has been no increase in harm reduction 
funding since 2007, when US$160 million (US$187 
million in 2016 prices) was estimated to have 
been spent on harm reduction.[8] This is despite 
the UN target of halving HIV transmission among 
people who inject drugs by 2015. This target was 
spectacularly missed, with UNAIDS reporting 
new HIV infections had, in fact, increased by 33% 
between 2011 and 2015.[9] It is also despite the 
indisputable evidence that harm reduction works, 
saves money and saves lives. It is frustrating to 
find that many of the recommendations and calls 
to action made in our previous reports on harm 
reduction funding need to be repeated here.[8] [10]
There has been no increase in harm 
reduction funding since 2007
Harm reduction funding in LMICs in 2016 equated 
to just four cents per day for every person 
injecting drugs.4 This differs hugely by country, 
ranging from less than one cent per day in six 
countries to over a dollar a day in four countries. 
Russia accounts for 20% of people who inject 
drugs in LMICs but only 1% of identified harm 
reduction spending. 
1.2.1 Where are harm reduction funds going? 
Harm reduction funding in LMICs in 
2016 equated to just four cents per 
day for every person injecting drugs. 
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Map 1: Variation in harm reduction funding levels in LMICs assessed as the number of cents  
per day per person injecting drugs5
Our research showed that the distribution of 
funds was not aligned with epidemiological 
evidence. Worryingly, upper middle-income 
countries have the largest share of people who 
inject drugs, but lower middle-income countries 
have the greatest share of harm reduction 
funding. China6 and Russia substantially shape 
this finding but it also reflects the predominance 
of international donors in the resourcing of harm 
reduction and their focus on low and lower-middle 
income countries.
6. Domestic investment data was only identified for Yunnan province in China, so a complete picture of spending in this country was not available.
7. While investment data was only identified for Yunnan province in China, it is safe to assume given the extent of programming in the country,  
national investment exceeds US$1 million.
Figure a: Share of people who inject  
drugs in LMICs & Share of identified  
harm reduction spending in LMICs
Upper  
middle-income  
countries
Lower  
middle-income  
countries
Lower income  
countries
HR Funding overall 2HR Funding overall 2
Number of  
people who  
inject drugs
Total harm  
reduction funding  
5. As spend data for China was only from one province and the population size estimate of people who inject drugs in Brazil is considered a vast 
overestimate, these two countries are excluded from this map so as not to misrepresent the situation. 
For both low and lower middle-income countries, 
the average spend per person injecting drugs 
per day is around 9 cents, but that falls to 2 cents 
per day for the upper middle-income countries. 
Less than one-quarter of upper middle-income 
countries spend more than 10 cents a day. 
Harm reduction spending accounts for just 
0.8% of all HIV spending in upper middle-
income countries. Despite international donors 
withdrawing from many upper middle-income 
countries, sizeable national government 
investment (over US$1million) has only been 
identified in a handful of these countries, namely 
China,7 Malaysia, Iran, Kazakhstan and Thailand. 
Globally, the majority of harm reduction funding 
was for Asia and Eastern Europe, with Latin 
America accounting for a small proportion and 
Sub-Saharan Africa accounting for 16%. When 
compared with the share of the number of people 
who inject drugs, Latin America and Asia receive 
a smaller proportion of spend while Sub-Saharan 
Africa receives a greater proportion. Countries 
in the Middle East and North Africa (MENA) 
also receive a larger proportion of spend, but 
this reflects the relatively large harm reduction 
investment in Iran.
Harm reduction spending accounts 
for just 0.8% of all HIV spending in 
upper middle-income countries. 
• Albania
• Argentina
• Ghana
• Iraq
• Libya
• Macedonia
• Maldives
• Syria
• Lebanon
• Russian Federation
• Mexico
• Bulgaria
• Dominican Republic
• Madagascar
• India
• Romania
< 4 cents 4 – 10 cents 10 cents – US$1 > US$1
• Mongolia
• Belarus
• Afghanistan
• Pakistan
• Uzbekistan
• Azerbaijan
• Nepal
• Kosovo
• Ukraine
• Kazakhstan
• Malaysia
• Serbia
• Indonesia
• Lao PDR
• Cambodia
• Tajikistan
• Sri Lanka
• Thailand
• Moldova
• Congo (Democratic Republic)
• South Africa
• Iran
• Armenia
• Tunisia
• Sierra Leone
• Philippines
• Tanzania
• Egypt
• Bosnia & Herzegovina
• Mozambique
• Vietnam
• Kyrgyzstan
• Georgia
• Bangladesh
• Mauritius
• Myanmar
• Nigeria
• Kenya
• Senegal
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where government support is lacking, donor 
withdrawal has led to programme closures and 
rapid increases in HIV and hepatitis C among 
people who inject drugs, most notably in Central 
and Eastern Europe. There are fewer donors 
providing substantial specific funding for harm 
reduction now than a decade ago, while there has 
also been a significant decrease in bilateral aid 
for harm reduction and data suggest a decrease 
in Global Fund for AIDS, Tuberculosis and Malaria 
(Global Fund) harm reduction allocations since 
2011. All these factors combined are likely to have 
had most impact on harm reduction in upper 
middle-income countries, where the majority  
of people who inject drugs live. 
UN agencies play an important role in providing 
guidance and technical support to governments,  
a factor which will be crucial for increasing 
domestic financial commitments to harm 
reduction. However, reductions in donor 
contributions to UNAIDS had a direct effect on  
the agencies receiving funds to work on HIV/AIDS, 
including the United Nations Office on Drugs and 
Crime (UNODC), the lead UN agency on HIV and 
drugs. This resulted in a 50% reduction in core 
funding allocations to UNODC between 2015 
and 2017.[15] In  2017, member states adopted a  
Commission on Narcotic Drugs (CND) resolution 
which encourages member states and other  
donors to make extra-budgetary contributions 
to the HIV work of UNODC to secure adequately 
financed, targeted and  sustainable responses 
related to HIV and drug  use, and HIV 
in prison settings. 
Broadly, however, it is projected that international 
donor funds for the HIV response are likely to 
reduce further in the future, with the emphasis 
moving towards health system strengthening and 
universal health coverage. Innovative financing 
and collaborations with the private sector also 
increasingly feature in funding strategies. The 
challenges for sustainable harm reduction funding 
within this shifting environment are formidable. 
Now more than ever, the tenacity and drive of  
the harm reduction movement is needed to 
sound the alarm. Governments, multilaterals  
and donors are failing people who use drugs.  
In 2010, we stated that ‘funds are needed, and 
they are needed now’.[8] In 2018, the same is true. 
Of the US$188 million funding 
for harm reduction in 2016, the 
majority (US$120.7 million, 64%) 
was international donor funding. 
Figure b: Proportion of harm reduction funding and people who inject drugs by region
Funding for HR overall 3Funding for HR overall 3
People who  
inject drugs
Harm reduction  
funding  
Sub-Saharan Africa
Middle East and North Africa
Latin America
Eastern Europe and Central Asia
Caribbean
Asia
1.2.2 The wider funding environment  
Harm reduction funding represented just 1%  
of the estimated US$19.1 billion spent by donors 
and governments on the HIV response in 2016.[14] 
Recent years have seen dramatic increases  
in domestic investment in some elements of 
national HIV responses, with latest figures 
indicating that states are now providing the 
majority share of HIV investment.[14] However, 
most national governments have not prioritised 
harm reduction, or wider key population 
programming in their spending, even where 
the epidemic is concentrated among these 
groups. Of the US$188 million funding for harm 
reduction in 2016, the majority (US$120.7 million, 
64%) was international donor funding. Very few 
countries have sufficient transparency of national 
expenditure data on harm reduction to identify 
the source and amount of domestic funding, 
but in countries with available data, governments 
provided an average of one-quarter of harm 
reduction funding. By comparison, domestic 
resources accounted for 57% of HIV funding  
in LMICs.[14] 
International donor priorities have shifted in 
recent years, with most donors reducing aid to 
richer countries in favour of those with low income 
and high epidemic burden. In some countries, 
Harm reduction funding 
represented just 1% of the 
estimated US$19.1 billion  
spent by donors and governments 
on the HIV response in 2016. 
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2. International  
donor funding  
for harm reduction
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International donors invested an estimated 
US$121 million in 2016, accounting for 64% of all 
identified harm reduction funding. In 2007, HRI 
estimated donor investment to be US$136 million.8 
This difference represents a 24% decrease in real 
terms. In other words, harm reduction funding 
from international donors is one-quarter less than 
it was a decade ago.[8] 
2.  International donor funding for harm reduction
2.1 An overview of international donor support for harm reduction
Harm reduction funding  
from international donors  
is one-quarter less than it  
was a decade ago.
2.1.1 Which donors are funding harm reduction? 
The Global Fund remains the main international 
donor for harm reduction, contributing two-thirds 
(US$80.8 million) of all identified donor funding 
in 2016. Harm reduction is more reliant on the 
Global Fund now than it was a decade ago,  
when it provided one-third of all donor funds. 
During this time, bilateral funding has reduced 
considerably. The majority of donor governments 
that were providing bilateral harm reduction 
funding in 2007 now report that their support is 
predominantly channelled through multilateral 
organisations. Only 27% of donor funding for 
harm reduction was provided bilaterally compared 
to 79% of donor funding for HIV in 2016.[16]
The US government is an exception to this, 
providing US$25.8 million of harm reduction 
funding to LMICs in 2016 through the President’s 
Emergency Plan for AIDS Relief (PEPFAR), 
making it the second largest source of harm 
reduction funding. The Netherlands Ministry of 
Foreign Affairs (MoFA) was the only other donor 
government with harm reduction funds identified 
for 2016, amounting to US$4.1 million. 
Information was provided by 14 international 
donors (comprised of government, multilateral 
and philanthropic donors), 10 of which were able 
to identify harm reduction funding (Table 1). In 
2007, there were eight donors that reported harm 
reduction investments of over US$5 million,9 but 
in 2016, only two donors reported this level of 
investment: the Global Fund and PEPFAR. Between 
them, the two provided 88% of all harm reduction 
donor funding in 2016.
8. This would be US$159 million in 2016 terms.
9. In 2016 prices.
Between them, PEPFAR and the 
Global Fund provided 88% of all 
harm reduction donor funding  
in 2016.
Donor Funding 
identified for 
harm reduction 
in 2016 (in US$ 
millions)
Source and notes
The Global Fund to Fight AIDS, 
Tuberculosis and Malaria 
(Global Fund)
80.811 Survey response: harm reduction allocation  
for period 2014-2016 provided by Global Fund  
divided by 3 for 2016 estimate
President’s Emergency Plan 
for AIDS Relief (PEPFAR)
25.8 Expenditure data from PEPFAR dashboards
International Harm  
Reduction Development 
(IHRD) Program, Open  
Society Foundations
4.9 Survey response 
Netherlands Ministry of  
Foreign Affairs (MoFA)
4.1 Information provided through Netherlands MoFA
United Nations Office on 
Drugs and Crime (UNODC)
1.5 Survey response: health services only,  
adjusted for double counting with PEPFAR data
Robert Carr Civil Society  
Networks Fund (RCNF)
1.2 Survey response
International HIV/AIDS  
Alliance (IHAA)
1.0 Survey response: adjusted for double counting with 
Netherlands MoFA data
Elton John AIDS Foundation 
UK
1.0 Survey response
DROSOS Foundation  
(Switzerland)
0.3 Information on harm reduction specific projects  
provided by DROSOS Foundation
Elton John AIDS Foundation 
US
0.1 Survey response
Table 1: International donor funding for harm reduction in 201610
10. See methodology section for more information.
11. This amount represents one-third of allocations for harm reduction under new grants in the 2014-2016 period.
12. Regions are consistent with those used in HRI’s Global State of Harm Reduction reports, with the exception that Latin America and the Caribbean are 
considered one region in this report.
13. Information on the country/region of funding was provided for US$96.5 million of the international donor spend identified. For the remainder, funding 
was either global, for example for international networks or in the case of UNODC, it was not possible to determine how much was provided for individual 
countries/regions.
2.1.2 Where are international donors funding harm reduction?  
Regional perspective12
Thirty-seven per cent of identified donor funding 
went to Asia, with a slightly lower percentage 
(34%) going to Eastern Europe and Central Asia 
(EECA). Around one-quarter (24%) was directed to 
Sub-Saharan Africa, with small percentages going 
towards MENA countries (2%), and countries in 
Latin America and the Caribbean (3%).13
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ASIA
EECA
LAC
MENA
SSA
Int donor Funding 1
Ukraine14 was the greatest beneficiary of 
international donor harm reduction funding in 
2016, receiving US$14.8 million and accounting for 
15% of all identified funding and 42% of all EECA 
funding. Similarly, in 2016 Vietnam accounted for 
a third of the funding identified for Asia (35%) and 
the second largest share of international donor 
funding (14%). Only three other countries received 
over 5% of the total donor funding pot for harm 
reduction (Kenya, Nigeria and Myanmar; Table 2).
Country Funding  
(in US$ 
millions)
% of total 
global  
funding*
Ukraine 14.8 15%
Vietnam 13.2 14%
Kenya 7.0 7%
Nigeria 6.9 7%
Myanmar 6.4 7%
South Africa 4.1 4%
Indonesia 3.9 4%
Georgia 2.9 3%
Pakistan 2.2 2%
India 2.1 2%
* total global funding where a beneficiary country is identified
Table 2: : Top 10 beneficiary countries 
of international donor harm reduction 
funding in 2016
Figure c: Percentage of international 
donor harm reduction funding by region
14. The Global Fund allocation to Ukraine includes ARV treatment identified as going to people who inject drugs.  
  Only one other country has this. It has been left in the analysis to make it consistent with previous funding estimates. 
Country income status perspective
The majority of international donor funding goes 
to lower middle-income countries, which receive 
78 cents of every dollar spent. Despite the fact that 
two-thirds of people who inject drugs live in upper 
middle-income countries, only 17 cents in every 
dollar spent goes to these countries. International 
donors contribute just 3 cents per year towards 
harm reduction for each person injecting drugs in 
upper middle-income countries. This compares to 
24 cents in lower middle-income countries and 32 
cents in the low income countries.
People who  
inject drugs
Donor funding  
for harm reduction
Int Funding for HR 2Int Funding for HR 2
Figure d: Proportion of international 
donor funding and people who inject 
drugs by country-income status
There are 11 LMICs reported to have more than 
100,000 people who inject drugs15, seven of which 
are upper middle-income countries. Despite these 
seven countries being home to 5.6 million people 
who inject drugs, they were allocated a combined 
total of only US$4.4million of donor funding in 
2016. This compares to US$32.3 million in harm 
reduction donor funding provided to the other 
four countries – all lower middle-income – where 
2.4 million people who inject drugs live.
15. The 11 low and middle-income countries are China, Russia, India, Brazil, Ukraine, Vietnam, Iran, Malaysia, Mexico, Kazakhstan and Pakistan. It should be    
noted that the population size estimate for people who inject drugs in Brazil is considered an overestimate, with recent unpublished research suggesting 
very few people inject drugs in the country. Removing Brazil from this list would not however, change the overall disparity.
16. PEPFAR use the term medication assisted treatment, or MAT. The package also included HIV testing, counselling and treatment, STI prevention and 
treatment, condom demonstration and distribution for people who inject drugs and their partners, targeted behavioural interventions and IEC materials, 
TB diagnosis and treatment and vaccination, and diagnosis and treatment of viral hepatitis.
Harm reduction funding in Kenya
Kenya has both a generalised HIV epidemic and a concentrated epidemic with prevalence among 
the general population of 6% and 18% among people who inject drugs.[17] It is estimated that 
people who inject drugs account for 4% of new HIV infections annually, with about 30,000 people 
injecting in the country. The implementation of harm reduction interventions is a relatively new 
activity; between 2009 and 2012 only US$0.08 million out of US$496 million for prevention and 
US$2,466 million for the HIV response was allocated to harm reduction programmes.[18]
The United States Government invested US$5.5 billion in Kenya’s HIV response between 2004 and 
2017. Investment in harm reduction services increased in 2013 when PEPFAR activities included 
the provision of a package of interventions for people who inject drugs in high burden areas, 
including opioid substitution treatment (OST).16 
PEPFAR expenditure on OST increased from US$0.9 million in 2014 to US$2.7million in 2016 with 
a target of scaling-up coverage in three counties: Mombasa, Nairobi and Kalifi. A breakdown of 
PEPFAR expenditure shows that a sizeable proportion of the US$2.7 million invested in OST during 
2016 went to capacity building, with expenditure on health systems strengthening US$0.5 million, 
training US$0.15 million and construction and renovation US$0.6 million. Similarly, health systems 
strengthening accounted for just over one-quarter (US$0.6 million) of the US$2 million expenditure 
on HIV prevention for people who inject drugs.
Funding of commodities for OST was covered predominantly by PEPFAR (91%) with only 9% 
coming from national sources.[19] The 2017 Country Operational Plan, however, states that PEPFAR 
will not procure OST in 2018 although sites will be supported by mentorship, quality assurance and 
human resources.[19] The Global Fund also provides financial support for harm reduction in Kenya, 
amounting to an estimated US$1.6 million in 2016. The 2017 concept note for the Global Fund 
suggests that OST will now be partly supported by Global Fund money. 
Funding was also provided in 2016 through the International HIV/AIDS Alliance and the Dutch 
Government’s PITCH programme, as well as the DROSOS Foundation, while national funding 
remains low for harm reduction and prevention in general. This over reliance on uncertain donor 
Upper  
middle-income  
countries
Lower  
middle-income  
countries
Lower income  
countries
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Harm reduction funding in Kenya (continued)
support risks the sustainability of the response and leaves services in a precarious situation.  
The Kenya AIDS Strategic Framework (2014 to 2019) talks of a move from crisis management to 
strategic and sustainable mode, but highlights the fact that prevention is lagging behind in the 
national response.[20] 
In 2017, Kenya joined the Global HIV Prevention Coalition and committed to scaling up HIV 
prevention programmes, including among people who use drugs, in order to meet global  
and national targets to end AIDS by 2030. Funding for key populations prevention targets  
is estimated to increase by US$4.1 million between 2016 and 2020, from US$11.5 million to  
US$15.5 million.[21] However, it is not specified if the increased funding will be coming from 
domestic or international resources.  
2.1.3 What harm reduction interventions are funded by international donors? 
In 2016, the majority of the identified international 
donor funding for harm reduction was earmarked 
for the provision of health services and for 
capacity building. It was not possible to gather 
comprehensive data disaggregated by harm 
reduction intervention from most donors. As 
donor funding for harm reduction is almost 
always derived from HIV budgets, it follows that 
funding would be directed to the most effective 
interventions to prevent HIV among people 
who inject drugs: NSP and OST. However, the 
research found that both of the largest donors 
to harm reduction, the Global Fund and PEPFAR, 
had substantial grants in countries where these 
priority interventions were either not in place, or 
were very limited. Funds for NSP and OST together 
represented about one-third of Global Fund 
monies for harm reduction. 
Most donors were not able to provide funding 
amounts for harm reduction interventions that 
may not be prioritised under HIV budgets, for 
example, funding for overdose prevention, 
hepatitis, harm reduction for stimulant use and 
harm reduction in prisons. 
Overdose is one of the most common causes of 
death among people who inject drugs and are 
living with HIV. Despite being part of the UN-
recommended package of interventions, peer 
distribution of naloxone remains very limited 
in LMICs and is likely to have received very little 
dedicated funding from donors in 2016. Over 80% 
of people who inject drugs who are HIV positive 
also have the hepatitis C virus.[22] Treatment is 
available, but access remains limited for this 
population. Despite this, donors are not allocating 
substantial funds to this life-saving treatment  
and ensuring integration with harm reduction  
and HIV programmes in LMICs. 
Similarly, while several donors indicated that 
funded programmes may be reaching people 
who use amphetamine-type stimulants, most 
stated that they were not the main target of 
interventions. The only donor who explicitly noted 
their financial support for harm reduction services 
targeting non-injecting stimulant users in 2016 
was OSF.17 UNODC, the Global Fund and PEPFAR 
reported funding for harm reduction in prisons.18  
While UNODC was not able to estimate the extent 
of this funding, for the Global Fund and PEPFAR 
it was indicated that this represented minimal 
proportions of overall harm reduction funding. 
This overall picture is somewhat inevitable given 
that almost all harm reduction funding stems 
from HIV budgets, but it does raise an important 
concern. Harm reduction has applicability beyond 
HIV prevention, in reducing health, social and 
economic harms that can be related to drug use 
and in improving the quality of life for people who 
use drugs. In short, we need to look beyond HIV 
donors to fund harm reduction. 
2.1.4 The crucial role of international donors in funding harm reduction advocacy 
In 2016, of 158 countries and territories where 
injecting drug use has been reported, 68 still  
have no NSP, and 78 have no provision of  
OST.[2] The harm reduction funding crisis remains  
a crisis of political support for harm reduction  
in many countries. Gains made in increased 
domestic investment in harm reduction are  
far from proportionate to the gains made in 
domestic investment in HIV programmes overall. 
The responsibility is with exiting donors, UN 
agencies and crucially, civil society organisations  
to call on governments and support them to  
step up and fund these life-saving programmes. 
Strong advocacy requires secure and sustained 
funding for civil society, including networks of 
people who use drugs, but this is rarely prioritised 
in domestic funding. International donors have  
a crucial role, now more than ever, in funding  
harm reduction advocacy. 
Funding for advocacy, human rights work and 
policy reform was estimated to be US$9.8 million, 
representing 8% of all international donor funding 
for harm reduction. OSF invested 75% of its total 
expenditure for harm reduction on advocacy work 
in 2016, equating to US$4.2 million, the largest 
amount identified. Of OSF’s total expenditure,  
26% went to Latin American and Caribbean 
countries, principally Brazil and Colombia.  
This is in contrast to overall donor expenditure 
where very little went to these countries  
(2.5% overall, including OSF’s contribution).
Robert Carr civil society Networks Fund (RCNF), an 
important pooled funding mechanism dependent 
on replenishment from donors, also primarily 
funds advocacy work, with US$1.2 million worth 
of harm reduction funding identified in 2016. 
Around half of this goes to the Harm Reduction 
Consortium, which was funded by the UK’s 
Department for International Development (DFID) 
between 2006 and 2012, but has since been 
supported by core funding from RCNF. All three of 
the main consortia funded - the Harm Reduction 
Consortium, the INPUD-ANPUD Consortium 
and Eurasian Regional Consortium – have been 
awarded lower funding amounts in 2018.
In 2016, it is estimated that 3% of Global Fund 
money was allocated to advocacy, amounting  
to US$2.6 million. 
Other donors such as PEPFAR support advocacy 
work, but it has not been possible to identify the 
amount of funding. Some information is contained 
in PEPFAR Country Operation Plans, showing that 
there is funding for advocacy and policy work, for 
example in Central Asia.
Elton John AIDS Foundation (EJAF) in the UK and  
US identify a small amount of funding going 
towards policy and advocacy work, representing 
5% and 10% of their total expenditure, 
respectively. EJAF UK states that it expects to 
increase funding for HIV and harm reduction 
advocacy in Eastern Europe and Central Asia,  
with a new grants strategy to be released in 2018.
17. In 2017/18, the German Government has supported exploratory research and policy activities on harm reduction for stimulant use. There may have been 
some funds supporting this work in 2016 (the focus year of this study) however, it was not possible to obtain financial information from the donor. 
18. This information was reported to HRI in survey responses.
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While the above comprise identified funds 
supporting advocacy activities of civil society  
and networks, it is important to acknowledge the 
role of UN staff, particularly within UNODC, but 
also WHO and UNAIDS, in advocating for harm 
reduction approaches in LMICs.19 The recent 
funding cuts to UNAIDS, therefore, also pose 
concerns for harm reduction advocacy. 
Recommendations:
l   International donors must increase their funding 
for harm reduction in LMICs in order to meet 
commitments to ‘leave no one behind’ and 
ensure that their funding for harm reduction  
is used for priority interventions which will  
have the most impact: NSP and OST. 
l   International donors, including donor 
governments, must ensure full replenishment for 
the Global Fund and the Robert Carr civil society 
Networks Fund, and ensure that the Joint UN 
Programme on HIV/AIDS (in particular UNODC as 
the lead agency on HIV and drugs) is sufficiently 
funded to achieve the Fast Track Strategy to end 
AIDS by 2030. 
l   International donors must have an adequate 
transition plan in place when withdrawing or 
decreasing funding for harm reduction. In the 
event that transition strategies are not successful, 
contingency funds must be available to ensure 
there is no gap in harm reduction funding. 
l   In countries where donor withdrawal has resulted 
in a funding gap for harm reduction, international 
donors must reinstate funding or provide 
emergency funding options to ensure services 
continue to operate.
l   More broadly, international donors should 
ensure financial support for overdose prevention, 
including naloxone, harm reduction in prisons, 
treatment for hepatitis C and harm reduction 
interventions for stimulant use. 
l   International donors must increase their funding 
for harm reduction and human rights advocacy 
at national, regional and international levels, 
including support for networks of people who 
use drugs. Civil society-led advocacy for harm 
reduction funding will be critical in supporting  
the transition from donor to domestic funding.  
l   Donor governments must not rely on 
contributions to multilaterals and the UN  
to meet their harm reduction commitments. 
Bilateral funding for harm reduction must  
be reinstated and targeted to the countries 
where it is most needed, regardless of country 
income status.
19. UN salary and office costs were not included in this analysis. 
2.2 The Global Fund to Fight AIDS, Tuberculosis and Malaria
The Global Fund, created in 2002 to fight three 
diseases, remains the leading international donor 
investing in harm reduction. At its peak in 2010, 
an estimated US$135 million was allocated to 
harm reduction, representing around 10% of 
the total HIV and HIV/Tuberculosis commitment. 
That year, the Global Fund articulated its explicit 
support and endorsement for harm reduction 
approaches[23] and used a mechanism called 
the ‘MARPS reserve’ to earmark funds for most-
at-risk-populations. A significant change to the 
funding model was announced in 2013, requiring 
allocations to be based on country income level 
and disease burden.[24] In line with the UNAIDS 
Fast-Track Strategy to End AIDS by 2030 and donor 
trends, the Global Fund is slowly moving away 
from funding middle-income countries. During 
the 2017-2019 period, all upper middle-income 
countries and all lower middle-income countries 
with low or moderate disease burden are required 
to build plans to transition from Global Fund to 
national government support.[25] As three-quarters 
of all people who inject drugs live in middle-
income countries (27% in lower middle-income 
and 55% in upper middle-income countries). 
the potential of this funding approach to have  
a devastating impact on harm reduction and  
the goal to end AIDS by 2030 among people  
who inject drugs is a major concern.
2.2.1 How much does the Global Fund invest in harm reduction?  
Assessing the extent to which Global Fund  
monies go towards harm reduction programmes 
is extremely difficult. Past investigations have  
been one-off exercises rather than part of an 
ongoing, systematic process.20 [26] Several factors 
limit a full understanding of the situation. 
Firstly, all the exercises to date have used 
allocation rather than expenditure data,  
meaning that they represent intended, rather  
than actual investments. 
Secondly, the estimated absorption rate for  
Global Fund grants is around 70%21 and has  
not been factored into this analysis, so we  
can assume that the data reported here  
over-estimate actual expenditure. 
Thirdly, allocations are reported by funding period 
rather than by the year funds are allocated for. 
The move to a three-year allocation-based funding 
model and the different timings on applications 
for funding means that it has only been possible 
to identify harm reduction funding over the 
full three-year allocation period rather than for 
individual years. Therefore, annual funding has 
been estimated by simply dividing the three-year 
period total by three.22  
At a country level, where possible, data have  
been cross-checked with key contacts within  
that country. 
Over the 2014 to 2016 period, it is estimated 
that US$240 million was allocated to harm 
reduction, around US$80 million per year. 
Two-thirds (67%) was earmarked for health 
interventions listed within the comprehensive 
package for people who use drugs,23 while  
just under one-quarter (23%) was allocated for 
capacity building/training and 3% was allotted for 
advocacy. In terms of the key interventions, 13% 
of the harm reduction allocation was for OST and 
21% was for NSP. Countries with the largest harm 
reduction allocations, in descending size order, 
were Ukraine, Vietnam, Myanmar, South Africa, 
Nigeria, Indonesia, Georgia, Pakistan, Tajikistan, 
Russian Federation and Moldova. However, 
expenditure data may look quite different to the 
allocation figures for some of these countries. 
In Nigeria, for example, US$8 million allocated 
to harm reduction for the 2014-2016 period is 
likely to have ended up being redirected to more 
politically palatable HIV programming that will 
have little HIV prevention impact for people who 
use drugs.[2] 
20. However, internal efforts are now underway to assess key population investment, including for people who inject drugs and key performance indicators 
on this have been developed.
21. See Table 4.1 for difference between approved funding and disbursed funding: https://reliefweb.int/sites/reliefweb.int/files/resources/Full%20
Report_1011.pdf 
22. Matching allocations to years would require the extraction of detailed information from each grant. Implementation periods for the 2014-2016 grants vary 
and the majority ended December 2017 but it has not been possible to factor this into the analysis as grant start and end dates were not provided by the 
Global Fund.
23. This included funds for the following: comprehensive condom and lubricant programming, NSP, OST, overdose prevention and management, including 
naloxone, behavioural interventions, pre-exposure prophylaxis, HIV testing and counselling, HIV treatment and care, prevention and management of viral 
hepatitis, prevention and management of TB, prevention and management of mental health conditions, sexual and reproductive health interventions, 
including contraception, diagnosis and treatment of STIs, cervical screening.
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Without country-level expenditure data 
disaggregated by intervention, it is not possible 
to say with any certainty what has been spent on 
harm reduction in a country, but there are some 
conclusions that can be drawn by cross-checking 
with our knowledge of existing service provision. 
Several countries with substantial harm reduction 
allocations from the Global Fund (the largest of 
which were for South Africa and Nigeria) have no, 
or very limited provision of NSP and OST. These 
are the most effective interventions to prevent  
HIV for people who inject drugs. It is expected  
and right that a proportion of Global Fund 
allocations in these countries are for advocacy 
and policy reform, with a view to introducing and 
scaling up NSP and OST services. But the size of 
these grants suggests that these allocations are 
also for interventions that, while important, will 
not succeed alone in preventing HIV and viral 
hepatitis among people who inject drugs. The 
Global Fund must ensure that funds are allocated 
to priority interventions that will have the most 
impact on epidemics. 
2.2.2 Global Fund harm reduction investments over time 
It is important to assess Global Fund investments 
over time to see whether the change from the 
rounds-based funding model to the allocation 
model has had an impact on harm reduction 
funding. Figure e shows rounds-based Global Fund 
allocations for harm reduction by the year that 
the funding was intended for.24 Harm reduction 
allocations increased steadily between 2003 
and 2008, with bigger increases between 2008 
and 2011. However, over the latter period the 
proportion of overall harm reduction funding  
that went to NSP and OST decreased slightly,  
and these interventions continued to account  
for a lower proportion of harm reduction funding 
than in the early years of the Global Fund’s 
activity. It is between 2010 and 2011 that the 
impact of the key 2010 initiative – the MARPs 
Reserve, a dedicated pot of money for most-at-risk 
populations – can be clearly seen. This influence, 
and to a lesser extent that of Round 2 and  
Round 9 grants with harm reduction components, 
continues into the 2014-2016 period. However,  
the impact of these grants is significantly 
decreased by 2016, with many countries having 
transitioned onto new grants under the allocation 
funding model. 
Unfortunately, data on new grants agreed  
under the allocation model for 2014-2016 were 
not provided by the Global Fund in sufficient  
detail to enable analysis over time. As described 
earlier, it is estimated that within these new 
grants for 2014-2016, harm reduction allocations 
amounted to US$80.8 million (an estimate  
reached by dividing the aggregate figure by  
three). This is marked separately on the graph 
opposite for guidance. 
24. Analysis was carried out using data that informed Bridge et al (2016). Trend data are adjusted to 2016 prices using the Bureau for Labor Statistics CPI 
inflation data for January each year. See methodology for more details. 
Figure e: Global fund rounds-based allocations to harm reduction 2003-2016 (US$ 2016 prices)25 
25. Data in this graph differ from the published data in Bridge et al. (2016) as they have been re-calculated for year of intended spend rather than year of 
allocation. Data for new grants in the 2014-2016 allocation period were provided in aggregated form rather than at grant level so it has not been possible 
to analyse funds by year of allocation, as for the rounds-based funding data.
26. For consistency and due to differences in the form of the data provided, the US$80.8 million allocated under new grants for 2014-2016 is used in the 
calculations in the rest of the report. 
27. US$10,354,540,000 for 2008-2010 (2010 to 2016 prices)
This limits the extent to which we can assess the 
impact of the change in funding model for harm 
reduction. However, there is an indication that 
harm reduction funding under the allocation 
model may be less prioritised than under some  
of the previous funding rounds. When the  
US$80.8 million estimate of per year funding 
is added to remaining rounds-based funding 
allocations for 2016, it suggests that harm 
reduction allocations for 2016 were 18% lower 
than that of 2011.26 Further granularity on the 
new grants for 2014-2016 is urgently needed to 
provide a clear picture of yearly allocation trends 
(which may still differ significantly from actual 
expenditure data). For this, the Global Fund  
must improve the way in which they monitor  
and record their funding allocations and 
ultimately, expenditure on harm reduction. 
Pending this, with the information available  
to HRI for this research, we deemed this a safe 
conclusion based on the evidence to hand.
This represents an 18% reduction of Global Fund 
allocations for harm reduction at a time when 
individual donor governments, such as the UK, 
have ceased bilateral funding of harm reduction 
and state that their contributions are now 
channelled through multilaterals such as  
the Global Fund.[27] This cannot be attributed  
to a decrease in the Global Fund’s overall budget, 
as between the 2008-2010 and 2014-2016 funding 
rounds, pledges to the Global Fund increased in 
nominal terms although they were stable taking 
inflation into account.27
120,000,000
100,000,000
80,000,000
60,000,000
40,000,000
20,000,000
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Harm reduction Health services NSP OST NSP & OST
New grants under 
the allocation 
model for 2014-
2016 included 80 
million per year 
for harm reduction 
when split evenly 
across the three 
year period.
Global Fund allocations for harm 
reduction were 18% lower in 2016 
than in 2011. This comes at a time 
when donor governments, such as 
the UK, have stopped bilateral harm 
reduction funding.
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Table 3: Pledges to the Global Fund during the four rounds between 2001 and 2016
2001 - 2007 2008 - 2010 2011 – 2013 2014 – 2016
9,187,430,331 9,381,162,826 9,543,457,752 10,427,725,858
Source: The Global Fund
Within rounds-based funding, harm reduction 
represented only 5% of the Global Fund’s total 
investment in HIV. This has reduced further and 
within new grants allocated in 2014-2016, harm 
reduction accounted for 4% of HIV investments.  
If the percentage had remained stable, investment 
in harm reduction would have been US$20 million 
(or 25%) higher in 2016.
The decline in funding for harm reduction by 
the Global Fund may reflect its changing funding 
eligibility criteria, which altered the geographical 
picture of the Global Fund’s presence. Almost 
one-quarter of the rounds-based harm reduction 
funding went to countries that did not receive  
a new grant in the 2014-2016 period. The focus 
has shifted to countries with low income and  
high disease burden and away from some of  
the countries with lower overall disease burden 
and higher income, but high need among people 
who inject drugs. Six of the 12 countries that 
previously received Global Fund funding, but  
are now listed as ineligible in either the 2017 
or 2018 lists, have HIV prevalence rates among 
people who inject drugs of over 5% (see table 4).28 
Table 4: Harm reduction data for countries with Global Fund harm reduction allocations  
between 2002-2016 but ineligible for HIV country grants on 2017 or 2018 eligibility lists
Country PWID  
population 
size  
estimate[2]
HIV  
prevalence 
among 
PWID
GF funding 
allocation 
2014-2016
Reason for 
becoming  
ineligible
Eligibility  
to apply for  
transition funds,  
or under the  
NGO rule,29  
or potential  
upcoming change  
in eligibility  
status
Albania 12,700 6.3 no Low HIV disease 
burden 
Eligible for  
transition  
funding  
2017-2019 
Algeria nk nk yes Moderate HIV 
disease burden
HIV disease  
burden went from 
moderate to high 
resulting in one  
determination of 
eligibility.30 
Argentina 65,829 
(64,500-
67,158)
3.5 no G20 country
Bosnia &  
Herzegovina
12,500 
(9,500-
15,500)
0.3 no UMIC with low 
HIV burden
Bulgaria 19,000 10.6 no Not on OECD 
list of ODA  
recipients
NGO rule. Round 2 
grant funds still being 
expended in 2017.  
China 2,580,000 6 no G20 country
Croatia 10,000 0.48 no UMIC with low 
HIV burden
Estonia 13,801 50-60 no High income 
country
Macedonia 15,000-
20,000
0.12 no UMIC with low 
disease burden
Became ineligible in 
2014, Round 10 grant 
funds still being  
expended in 2017.
Mexico 164,000 2.5 no G20 country
Romania 19,265 24.9 no Not on OECD 
list of ODA  
recipients
NGO rule 
Russian  
Federation
1,815,000 18-31 yes Not on OECD 
list of ODA  
recipients
NGO rule.  Change  
in income status from 
high to upper middle 
resulting in one  
determination  
of eligibility31 
Turkey nk 0.2 no UMIC with low 
disease burden
28. Algeria, Bulgaria, China, Estonia, Romania, Russia 
29. The NGO Rule provides an exception to the OECD DAC rule, stating that in countries with high disease burden (for example,  Russia, Bulgaria and 
Romania), civil society can access Global Fund support if there are ‘political barriers’ in the country. The term ‘political barriers’, however, is interpreted 
narrowly, as laws that criminalise provision of services. This interpretation enabled much needed funding in Russia in 2014-2018 on the basis of its  
legal prohibition of OST, amongst other factors, but does not capture Romania or Bulgaria. The political barriers criteria are assessed every three years  
in line with allocation cycle. For more information, see HRI’s briefing on the impact of the Global Fund’s eligibility policy on harm reduction at  
https://www.hri.global/files/2018/05/01/HRI-Briefing-April-2018.pdf  
30. Country components must be eligible for two consecutive eligibility determinations to be classified as eligible on the Eligibility List.
31. Country components under the NGO rule must be eligible for two consecutive eligibility determinations based on income classification and disease burden.  
The political barriers criteria required under the NGO rule are assessed every three years in line with the allocation cycle.
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Figure f: Proportion of country grants allocated 
to each region under rounds-based funding 
(2002-2014) and allocation model funding  
(2014-2016)32 
Map 2: Countries that received harm reduction support through Global Fund rounds-based funding 
(2002-2014) and allocation model funding (2014-2016)
Rounds-based 
funding  
2002-2014
Allocation 
model funding 
2014-2016
LAC 
SSA 
MENA 
ASIA
EECA
Despite the different time periods covered, it is 
clear that there has been a move away from the 
Global Fund contributing to programmes in EECA 
and more focus on countries in Sub-Saharan 
Africa. In addition, countries in MENA are now  
less likely to be receiving Global Fund money  
(see Figure f and Map 2). 
In the 2014-2016 allocation period, harm reduction 
accounted for 30% of HIV Global Fund allocations 
in EECA, 17% in MENA and 15% in Asia. 
Global Fund data show that the countries with the 
five largest total HIV allocations in 2014-2016 were 
all Sub-Saharan African countries (South Africa, 
Nigeria, Kenya, Tanzania and the Democratic 
Republic of the Congo). Harm reduction accounts 
for only 1.9% of the overall HIV allocations across 
these countries and is as low as 0.1% in Tanzania. 
This corroborates findings from a recent study 
showing that the proportion of prevention funding 
in Global Fund signed grant agreements in African 
countries fell well below the recommended 25% 
in 2014-2016 and that prevention across all key 
populations33 accounted for less than 3%.[28]
During the 2014-2016 allocation period, the Global 
Fund also made several multi-country and regional 
grants through its catalytic investment funding,34  
which had a harm reduction focus, including two 
in EECA, one in MENA, one in Asia, and three in 
Sub-Saharan Africa. Of these seven grants, five 
were solely harm reduction focused, collectively 
amounting to US$31 million, from a total of 
US$134 million for multi-country HIV grants.  
While most have not funded service provision,35 
these grants have provided a crucial opportunity 
to fund harm reduction advocacy and to focus on 
efforts to increase or establish domestic support. 
Multi-country grants also provide a mechanism 
for those countries ineligible for country grants on 
the basis of their income status, to access small 
amounts of funding (only 51% of countries in any 
multi-country application must meet the Global 
Fund’s eligibility criteria). 
However, the HIV multi-country funding allocation 
has now been reduced significantly and overall 
this will be US$50 million for the 2017-2019 grant 
period. Multi-country grant opportunities will be 
available for four regions only: Latin America and 
the Caribbean, EECA, MENA and Asia. These grants 
will not have a sole focus on harm reduction but 
will instead be targeted towards key population 
programme sustainability more broadly.[29] The 
current multi-country grants in Africa, which are 
advocacy-focused, will not be renewed when  
they expire.
32. Note that the time periods differ so the number of countries should not be compared.
33. Men who have sex with men, transgender people, sex workers and people who inject drugs.
34. Catalytic investments are described as ‘programs, activities and strategic investments that are not adequately accommodated through country allocations 
but that are essential to achieve the aims of the Global Fund Strategy 2017-2022 and global partner plans.’ They include matching funds, multi-country 
initiatives and strategic investments. For more information, see https://www.theglobalfund.org/en/funding-model/funding-process-steps/catalytic-
investments/ 
35. An exception to this was the MENA grant held by MENAHRA which included services as ‘advocacy model projects’. 
Source: Bridge et al. 2016; Global Fund
• Afghanistan
• Algeria
• Armenia
• Azerbaijan
• Bangladesh
• Belarus
• Bhutan
• Cambodia
• Georgia
• Indonesia
• Iran
• Kenya
• Kosovo
• Kyrgyzstan
• Madagascar
• Malaysia
• Mauritius
• Moldova
• Mongolia
• Myanmar
• Nepal
• Nigeria
• Pakistan
• Paraguay
• Philippines
• Russian Federation
• Sri Lanka
• Tajikistan
• Thailand
• Tunisia
• Ukraine
• Uzbekistan
• Vietnam
• Zanzibar
• Albania
• Argentina
• Bosnia & Herzegovina
• Bulgaria
• Burundi
• Cape Verde
• China
• Croatia
• Egypt
• Estonia
• India
• Jordan
• Kazakhstan
• Macedonia
• Maldives
• Mexico
• Montenegro
• Morocco
• Palestine
• Romania
• Serbia
• Syria
• Timor-Leste
• Turkey
• Benin
• Burkina Faso
• Cameroon
• Colombia
• Congo (Democratic Republic)
• Guinea
• Honduras
• Mali
• Senegal
• Sierra Leone
• South Africa
Received rounds-based  
and allocation model funding
Received rounds-based  
funding only
Received allocation model  
funding only
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2.2.3 A harm reduction lens on Global Fund allocation, eligibility and transition 
The two indicators now used to determine 
eligibility and to inform allocations for Global Fund 
funding are country income status and disease 
burden, with the underlying assumption that 
higher income countries should fund their own 
health responses. This has resulted in funding 
allocation reductions to middle-income countries, 
where most people who inject drugs live. Some 
countries are now ineligible for country grants or 
are included on the Global Fund list of countries 
that need to prepare for transition.[30] 
Several countries that have been heavily reliant on 
Global Fund allocations for harm reduction have 
seen dramatic reductions in their allocations for 
the period 2017-2019. For example, on a per-year 
basis, Moldova’s 2017-2019 allocation represented 
a 43% drop from 2014-2016.[31] It is telling that the 
Committee on Economic, Social and Cultural Rights 
(CESCR) recently raised concerns and included 
a call for the state to fund harm reduction in its 
concluding observations on the third periodic 
report of the Republic of Moldova: ‘The Committee 
is concerned ….that the harm reduction programmes 
for drug users face the withdrawal of international 
funding, which will result in fewer health services and 
an increased prevalence of hepatitis and HIV among 
drug users.’[32] 
Unfortunately, country income status and disease 
burden among people who inject drugs are not 
predictive factors for a government funding its 
own harm reduction response. The use of disease 
burden as a measure may in itself deprioritise  
HIV prevention efforts for people who inject  
drugs, by not allowing countries to seek funding  
to prevent epidemics before they become 
considered high burden. 
The challenges and complexities of transitioning 
from international donor funding to domestic 
financing are likely to be particularly pronounced 
for harm reduction. Governments often lack 
the political will to direct funding towards harm 
reduction and, even where it is present, they 
may lack technical expertise in harm reduction 
programming and/or mechanisms for social 
contracting necessary to fund civil society 
programmes. For some countries that became 
ineligible for HIV funding before a transition 
policy was developed, such as Romania[33] and  
Serbia,[34] the end of Global Fund grants led to 
programme closures and spikes in infections. 
Serbia subsequently became re-eligible for funds 
due to increases in disease burden. 
These situations clearly illustrate the importance 
of long transition periods and the availability 
of emergency or ‘bridge’ funding to avoid 
service closures and public health threats 
when international donor funding ends and 
governments are not ready to plug the funding 
gap left behind.[34]
Harm reduction funding in Kazakhstan 
There are around 117,000 people who inject drugs in Kazakhstan[2] with an HIV prevalence of 8.5% 
among this population.[35] The HIV epidemic is concentrated among key populations, with injecting 
drug use accounting for a large proportion of people living with HIV.[36]
Kazakhstan was allocated Global Fund money for harm reduction in 2003 (US$8.0m), 2007 
(US$7.5m) and 2010 (US$13.2m) with a large proportion of funding going towards needle, syringe 
and condom provision. As the country was one of the first in Eastern Europe and Central Asia 
(EECA) to gain upper-middle income status and had a low overall HIV prevalence, it became 
ineligible to apply for Global Fund grants in 2011, receiving no funding for new grants in the  
2014-2016 allocation period. Global Fund Round 10 funds were still supporting harm reduction 
during this period. The national government also provided support to the operation of around  
150 NSP sites within the country, reaching around 60% of people who inject drugs;[37] however,  
civil society note that government support was significantly reduced in 2017.[38] It is estimated  
that only 4.7% of the country’s total HIV budget goes towards prevention and only 2.7% for 
prevention activities is targeted to people who inject drugs. Access to OST has been restricted  
to pilot programmes at 10 sites in three cities, with less than 1% of people who use opioids 
accessing programmes.[37] 
Since 2010, new HIV infections have increased by 39% and increasing HIV prevalence among 
people who inject drugs has meant that Kazakhstan became eligible to apply for Global Fund 
grants again for the 2017-2019 period. The Concept Note for the Global Fund funding request, 
however, focuses on linkage to services and there is little indication that funds, international or 
national, will be used to increase access to OST. A number of barriers to OST expansion exist, 
including legal and political barriers, a hostile public environment, lack of trained staff, supply 
issues and cost. With an estimated funding gap of US$12.3 million,[39] the government will need  
to invest heavily to increase access to OST. However, threats to OST programmes reported in  
early 2018[40] have recently escalated, with the government considering ceasing their operation. 
This is a stark example of the political vulnerability of harm reduction programmes and has 
prompted civil society action in an attempt to hold the government to account.36 
36. See letter from Eurasian Harm Reduction Association delivered to the President of the Republic of Kazakhstan on June 26, 2018 here:  
http://harmreductioneurasia.org/wp-content/uploads/2017/06/1.1.pdf 
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The introduction of the Global Fund’s 
Sustainability, Transition and Co-financing Policy 
in 2016 goes some way to try and mitigate 
the negative potential of donor withdrawal. 
When countries become ineligible for country 
grants, they can apply for one allocation term 
(three years) of transition funding, provided 
they can meet the 15% government co-funding 
requirement. All applications are required to have 
a focus on key populations, equating to over 50% 
of budgets for lower middle-income countries 
and 100% of budgets for upper middle-income 
countries. An amendment made to the policy at 
the most recent Global Fund Board meeting in 
Macedonia in May 2018, now allows the Global 
Fund Secretariat to make case-by-case requests 
for a second allocation term of transition funding, 
where deemed necessary. To determine this, the 
Global Fund will examine several factors, such 
as the latest available HIV incidence data as well 
as domestic commitments, including ‘concrete 
commitments to finance services for key and 
vulnerable populations’.[41] 
Another concern for harm reduction is the 
challenge of maintaining the ‘quality’ of 
programmes through the transition to government 
support. In some cases increased government 
support has led to implementation being 
transferred from non-governmental organisations 
(NGOs) to public health facilities, resulting in the 
closure of community organisations previously 
providing the services. Public health facilities 
are unlikely to provide the same quality of harm 
reduction intervention as NGOs, as they are less 
likely to engage communities in service provision, 
or tailor services to the community’s needs. It is 
also reported that a common feature leading up to 
and during transition is an increase in programme 
coverage targets, which with stagnant or reducing 
funding levels can impact on service quality.[38]
Harm reduction funding in Ukraine 
Ukraine’s HIV epidemic is concentrated among key populations, with people who inject drugs 
accounting for approximately 28% of those living with HIV in the country. Harm reduction 
programmes are well established, with the Global Fund investing significant amounts of money  
for harm reduction in Ukraine, amounting to US$125.4 million over the period 2004-2014.37  
This support has allowed a large harm reduction programme to become available nationally  
with Global Fund-funded outreach prevention services reaching an estimated 62% of people  
who inject drugs in 2015.[42] In total, US$14.8 million of international donor funding for harm 
reduction was identified for 2016, the majority of which was from the Global Fund (76%). 
This investment in harm reduction has contributed to a decrease in HIV prevalence among people 
who inject drugs since 2012, leading to Ukraine being seen as an example of harm reduction 
success. Despite improvements, injecting drug use still accounts for between 20% - 40% of new  
HIV cases and an estimated 30,000 to 35,000 HIV-positive people who inject drugs were reported 
to be unaware of their status in 2015.[42] As of 2016, OST coverage is low and harm reduction 
services have been almost entirely funded by international donors.
However, as part of the Global Fund 2017-2019 grant agreement, the Government of Ukraine 
(GOU) committed to transition funding for key population prevention and OST away from the 
Global Fund to national funding. A Global Fund condition states that failure to do so will result in 
15% of the total grant being withheld, amounting to around US$27 million. The Global Fund’s 
Office of the Inspector General, however, raised concerns about the GOU’s readiness for 
transition, with no clear transition plan set out and uncertainty around the impact on reaching 
people who inject drugs when services are transitioned from NGOs to a government that 
criminalises drug use.[43] First procurements of OST give some hope for the Ministry of Health’s 
commitment to implementation of the transition plan.
However, questions have been raised around the quality of service provision in relation to 
OST and the role of the private sector and co-payment in delivering services. Initial delays in 
transitioning existing clients across to an OST programme financed by government raised 
doubts about the extent to which the government is able to scale-up OST provision as required. 
Community leaders are concerned about possible switching to the out-of-pocket payment to 
access OST treatment. Donor funding for advocacy will be crucial in ensuring a transition to 
government-financed OST programmes that are free, accessible and acceptable to people  
who use drugs. 
37. Data on Global Fund harm reduction funding in Ukraine includes antiretroviral treatment identified as provided to people who inject drugs.  
This amounted to US$23.3 million over the period.
It is clear that the Global Fund continues to be the 
most crucial donor for harm reduction. However, 
the allocation model, the strict eligibility criteria 
and transition away from middle-income country 
support are weakening the extent to which the 
Global Fund can fulfil this crucial role. Available 
data suggest that harm reduction allocations 
in 2016 are 18% less than that of 2011 and that 
emphasis on priority interventions may have 
reduced. While it is positive to see new countries 
include harm reduction components in their 
grants,38 [44] the Global Fund is retreating from 
countries where the need is greatest and domestic 
investment is lacking. 
Recommendations:
l  The Global Fund should reinstate the successful 
MARPs Reserve approach from Round 10 (2010) 
to ensure harm reduction funding is made 
available at the required levels for countries to 
scale up their responses to UN-recommended 
harm reduction coverage.
l  The Global Fund should not reduce or withdraw 
funds from countries until domestic support for 
harm reduction is in place. 
l  The Global Fund must do more to ensure that 
harm reduction is included in funding proposals 
where there is an epidemiological need for harm 
reduction interventions, in particular NSP and 
OST. To do this, the Global Fund must ensure 
that the Country Coordinating Mechanisms 
and Technical Review Panel include community 
representatives and harm reduction experts.
l  The Technical Review Panel should rule technically 
unsound any proposals from countries with 
injecting-related HIV epidemics, which do not 
include budgeted funds for the provision of 
priority harm reduction interventions.39 
l  The Global Fund must adopt a more flexible 
approach to funding eligibility to allow it to 
be more responsive to avert public health 
emergencies.40 Noting the availability of quality  
38. Including Benin, Burkina Faso, Burundi, Chad, Democratic Republic of Congo, Djibouti, Senegal, Sierra Leone and South Sudan  
http://www.globalfundadvocatesnetwork.org/wp-content/uploads/2016/07/Cost-of-Inaction-2016.pdf
39. Analysis of 119 proposals received by the Global Fund and reviewed by its Technical Review Panel showed that funding requests for key population 
programmes were often omitted from proposals even where the need had been identified. This information is taken from - Global Fund Advocates 
Network & International Civil Society Support. Investing in the Global Fund: The Cost of Inaction. Global Fund replenishment 2016. Amsterdam: 
International Civil Society Support; 2016
40. The eligibility policy currently requires countries to meet the eligibility criteria for two consecutive years before they can become newly eligible for an 
allocation. An eligibility criterion for high disease burden in concentrated epidemics is considered to be HIV prevalence of over 5%.
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data on HIV among people who inject drugs 
(and other key populations) is often limited and/
or outdated, when making decisions regarding 
eligibility and transitional funding, it is critical that 
the Global Fund relies not only on UNAIDS data, 
but also on data and evidence from wider sources 
including international and national civil society. 
l  The Global Fund must systematically monitor  
its allocations and spending on harm reduction. 
We welcome the plans to include key performance 
indicators to enable assessment of investment 
in key population programming and urge the 
Global Fund to share the results with national 
governments, donors and civil society to allow  
for transparent and coordinated planning. 
l  The Global Fund must maximise the potential for 
harm reduction to be supported with the US$200 
million catalytic investment allocation for HIV in 
2017-2019, and the now-reduced funding for 
focused multi-country grants, recognising the 
multiple draws on these funds.  
l  When working with national governments on 
increasing domestic support for harm reduction, 
the Global Fund should call on governments to 
critically evaluate the public health impact and 
effectiveness of their drug control spending.  
This should include recommending that they 
redirect funds away from ineffective drug law 
enforcement towards harm reduction.
2.3 Bilateral funding for harm reduction
2.3.1 PEPFAR
Since its inception in 2003, PEPFAR has provided 
an estimated US$70 billion for HIV/AIDS and 
tuberculosis programmes.[45] PEPFAR was  
the first, and remains, the largest donor to  
the Global Fund, and its pledges have been 
instrumental in leveraging funds from other donor 
governments.[46] PEPFAR’s commitment to reaching 
key populations with programmes is articulated 
in its strategic vision 3.0 and listed as one of five 
programmatic priorities: “Now more than ever, 
people who inject drugs, sex workers, and men who 
have sex with men face stigma and discrimination… 
If any one of our populations is left behind, we are 
all left behind and we will not control the epidemic.” 
– PEPFAR 3.0.[47] In 2016, PEPFAR allocated US$5.2 
billion for bilateral programmes, with a further 
US$1.4 billion allocated to the Global Fund.  
Our research shows that in that year, PEPFAR 
made the second largest donor contribution  
to harm reduction investment in LMICs. 
While the term ‘harm reduction’ is not used in  
its strategic vision and PEPFAR does not fund  
the purchasing of needles and syringes, PEPFAR’s 
prevention support does include three central 
elements of the UN-recommended comprehensive 
package to address HIV among people who 
use drugs:[48] ‘community-based outreach 
programmes; needle and syringe programmes 
(NSPs); and drug dependence treatment,  
including medication assisted therapy (MAT),41 
with methadone or buprenorphine and/or other 
effective medications as appropriate, based on 
the country context’.[49] Additional PEPFAR-funded 
activities, which may include harm reduction 
elements, include policy reform, training, 
capacity building, sexual transmission prevention 
programmes for people who inject drugs, 
community mobilisation and programmes  
that address non-injection drug use. 
The most significant limitation to PEPFAR as 
a harm reduction donor stems from the US 
domestic legislation which continues to prohibit 
the use of federal funds to purchase sterile 
needles and syringes.[50] The legislation does 
allow the use of federal funds for other needs of 
NSPs so, in practice, PEPFAR monies can be used 
to support the wider costs involved in providing 
NSP services, such as infrastructure and delivery 
costs. The implications of the 2017 expansion of 
the Mexico City Policy, or the ‘Global Gag Rule’, 
prohibiting US funds from going to NGOs that 
provide information, referrals or services related 
to abortion, will have far-reaching impact for 
women in LMICs, including women who use drugs. 
Crucially, this is a barrier to integrated sexual and 
reproductive health and harm reduction services, 
which are already rare and underfunded. 
PEPFAR support for harm reduction activities  
is limited to countries where there is existing 
PEPFAR activity and decisions on funding 
programmes for people who use drugs are  
taken on a country-by-country basis. PEPFAR  
has a focus on countries with large HIV epidemics 
and consequently Sub-Saharan Africa receives  
a considerable proportion of PEPFAR funds. 
41. PEPFAR, and the US government more widely use the term MAT instead of opioid substitution treatment, which is predominantly used elsewhere in the 
world.
2.3.2 How much does PEPFAR invest in harm reduction? 
PEPFAR demonstrates transparency in relation 
to its allocation and expenditure data, publishing 
several information sources online which can 
help to establish the extent of planned and 
actual investment in programmes for people who 
use drugs.42 Annual Country Operational Plans 
(COPs) underpin PEPFAR’s work at a country-
level and set out budget allocation and activity. 
Online ‘dashboards’ provide detail on budget 
allocations by areas of activity as well as actual 
expenditure, which has been tracked in all PEPFAR 
countries since 2014.[51] However, the way in 
which budget allocations and expenditure are 
categorised means they cannot be compared 
to assess whether plans came to fruition. This 
may be particularly important for key population 
programming where political opposition can be  
a barrier to implementation. 
A budget code, IDUP, captures funding allocations 
for HIV prevention programmes targeting people 
who use drugs (injecting and non-injecting),43 
whereas expenditure data is captured under two 
codes Medication Assisted Therapy (MAT)44 and 
Sexual and Other Risk Prevention, Injection Drug 
User (SORP-PWID).45 They also cover different 
time periods. Allocations in 2016 refer mostly to 
activities planned for 2017, whereas expenditure 
in a given year may be drawn from the previous 
year’s allocation or earlier. For 2016, PEPFAR’s 
expenditure relating to two expenditure codes 
(MAT and SORP-PWID) was recorded as being 
almost double the funding under the allocation 
code. Of note, PEPFAR also publish Sustainability 
Indices and Dashboards,[52] which assess the 
sustainability of national HIV responses in PEPFAR 
countries. This is not currently a tool that allows 
assessment of the sustainability of the harm 
reduction response.
The budget allocation for 2016 programmes 
targeting people who use drugs was US$14.0 
million, accounting for 0.3% of PEPFAR’s total 
bilateral budget.  
42. As PEPFAR does not categorise allocations or spending using the term harm reduction, it should be noted that there may be activities not strictly 
considered harm reduction being coded to these budget and expenditure lines.
43. The IDUP budget code includes HIV prevention activity for people who use drugs covering both NSP and OST. For a full description of the budget code see 
Appendix E.2.6: https://et.usembassy.gov/wp-content/uploads/sites/188/2017/04/COP17-Guidance_18JAN2017.pdf 
44. This programme area includes provision of opiates such as methadone for people who inject drugs. Expenditures related to outreach mobilization, and 
other ancillary services provided to opioid substitution therapy (OST) clients should be estimated and reported under the SORP-PWID program area.
45. This programme area includes services and support for individuals or small groups among injection drug users for the provision of HIV prevention 
interventions that are based on evidence and/or meet the minimum standards required.
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PEPFAR allocated 20% of its budget to HIV 
prevention broadly,46 ranging from 10% in  
Ukraine to 39% in Myanmar. But prevention for 
people who use drugs amounted to an average  
of 1.2% of the overall country and regional 
budgets, ranging from 0% in South Africa to  
19.7% in the Central Asia Regional programme.47  
However, upon examination of actual expenditure 
data for 2016, a total of US$25.8 million was 
spent on interventions for people who inject 
drugs, of which 34% was used to fund MAT 
programmes. This equates to 0.5% of PEPFAR’s 
total bilateral budget. PEPFAR reported to HRI that 
these funds covered NSP programme delivery 
costs, as well as capacity building and advocacy 
work related to service provision for people who 
inject drugs and related policy. This also includes 
some funding for prison programmes and there 
are plans for this funding to increase. The 2017 
Ukraine COP states that PEPFAR will support the 
Ministry of Justice to introduce MAT and a package 
of HIV prevention services for people who inject 
drugs within pre-trial detention centres and 
prisons.
In 2016, PEPFAR’s largest harm reduction 
expenditure was in Vietnam (US$5.3 million) 
although this was a reduction from 2015 
expenditure (US$8.2 million) and is anticipated to 
reduce further as the national government moves 
towards fully funding the provision of methadone 
and services to people who inject drugs. Most 
of the countries with significant harm reduction 
funding from PEPFAR also receive harm reduction 
funding from the Global Fund. India is the 
exception to this, where a total of US$2.1 million 
was spent by PEPFAR in 2016, 16% of which went 
to MAT. PEPFAR is the largest international donor 
for harm reduction in some countries, including 
Kenya and Tanzania. 
Of 22 PEPFAR country programmes with reported 
expenditure on programmes for people who  
use drugs in 2016, 12 are in countries with 
no NSP or OST services.48 The funds for harm 
reduction are relatively small when compared 
with the overall country grants, amounting to 
US$5.4 million in 2016, and representing 21% 
of PEPFAR’s harm reduction investment that 
year. With its emphasis on sub-Saharan African 
countries, PEPFAR has the opportunity to support 
the introduction of priority harm reduction 
interventions and prevent growing HIV epidemics 
among people who use drugs.[53] To do this, it  
must ensure appropriate funding goes towards 
priority interventions and the work necessary to 
ensure their effective implementation, including 
advocacy and policy reform. 
However, a recent review found that NSPs and 
policy reform were among the least frequently 
funded activities within PEPFAR supported 
programmes for people who inject drugs, 
mentioned in only 13% of reports, raising a 
concern that the most effective interventions 
for this key population are not receiving high 
enough priority.[54] In Nigeria, for example, PEPFAR 
expenditure was over US$4 million, but country 
operational plans for 2016 and 2017 do not 
mention NSP or OST. However, PEPFAR’s online 
dashboard indicates that the HIV prevention 
among key population targets was surpassed 
in 2016, with the indicator being ‘number of key 
populations reached with individual and/or small 
group HIV preventative interventions that are 
based on evidence and/or meet the minimum 
standards required’.
As the second-largest donor to harm reduction  
in LMICs, PEPFAR’s significant omission of funding 
for NSPs and policy reform leaves a considerable 
gap in essential financial support for the full  
range of harm reduction interventions 
recommended by both its own[55] and 
international guidance.[56] Furthermore, 
interventions such as the peer-distribution 
of naloxone and the provision of hepatitis C 
treatment do not feature in the majority of 
PEPFAR funded programmes. Naloxone is 
mentioned only three times within 2010-2015 
country and regional operational plans,49 while 
hepatitis C treatment receives similarly few 
mentions within planning documents. In order  
to maximise the impact of PEPFAR funds in 
curbing epidemics among people who use  
drugs, PEPFAR must ensure priority harm 
reduction intervention are supported.  
To provide a full picture of PEPFAR investment 
in harm reduction, it is also important to note 
several separate funding channels not captured 
within the online dashboards. Of note, PEPFAR 
headquarters has funded multi-year key 
populations-related initiatives, including the Key 
Populations Challenge Fund, the Key Populations 
Implementation Science Initiative, and the 
Local Capacity Initiative, which all potentially 
have some elements targeting people who use 
drugs, in addition to other key populations. 
Moreover, PEPFAR also committed US$10 million 
of funding to the 2016-2018 round of the RCNF 
and announced the creation of the US$100 
million Key Populations Investment Fund in 2016, 
which has yet to be implemented.[57] However, 
taken together with its direct funding for harm 
reduction programmes, this still represents  
a tiny fraction of PEPFAR’s overall budget. 
PEPFAR remains a crucial donor for harm 
reduction, both bilaterally and via its support  
for the Global Fund. However, more must be  
done to ensure that PEPFAR funds are used 
optimally and invested in the most effective, 
evidence-based harm reduction interventions  
for people who use drugs.
Recommendations:
l  PEPFAR should demonstrate its prioritisation of 
key populations by increasing the overall funding 
going towards these programmes – including 
for harm reduction – in line with epidemiological 
need. Despite PEPFAR being the second-largest 
harm reduction donor in 2016, this represents 
only 0.5% of PEPFAR’s overall bilateral funding. 
l  PEPFAR must fund all of the UN-recommended 
interventions to address HIV among people 
who use drugs, prioritising NSP (including 
the procurement of needles/syringes) and 
OST. PEPFAR should further fund treatment 
and prevention for hepatitis C and overdose 
prevention interventions, including naloxone. 
l  PEPFAR must make their allocation and 
expenditure data comparable so that this  
data can be meaningfully used to track  
whether money is being spent as planned. 
l  PEPFAR should ensure the Sustainability 
Indices and Dashboards can be used to assess 
the sustainability of the HIV response for key 
populations, including people who use drugs.
49. An online search using http://copsdata.amfar.org/about found one in Nigeria (2012) in relation to advocating for it to be listed as an essential medicine, 
one in Tanzania (2010) referring to work with the Ministry of Health and Social Welfare (MOHSW) in Zanzibar to introduce overdose prevention tools and 
Naloxone overdose treatment and one for the Central Asia Regional project (2012) to develop skills on overdose prevention and naloxone use. It should 
be noted that PEPFAR COPs/ROPs denote planned not reported activities.
46. The Planned Funding Prevention program area encompasses the following Budget Codes: Blood Safety (HMBL), HIV Testing and Counseling (HVCT), 
Injection Safety (HMIN), Injecting and Non-Injecting Drug Use (IDUP), Prevention of Mother to Child Transmission (MTCT), Sexual Prevention: Abstinence/Be 
Faithful (HVAB), Sexual Prevention: Other Sexual Prevention (HVOP), and Voluntary Medical Male Circumcision (CIRC).
47. PEPFAR dashboard data: https://data.pepfar.net/global 
48. Angola, Burundi, Haiti, Malawi, Mozambique, Namibia, Nigeria, Rwanda, South Sudan, Uganda, Zambia and Zimbabwe.
PEPFAR spent 0.5% of its total 
bilateral budget on harm reduction 
in 2016.
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2.3.3 Other bilateral funding for harm reduction 
When we conducted research in 2007, donor 
governments contributed a large share of global 
harm reduction funding through bilateral support 
to individual countries and regional programmes. 
For example, DFID was the second largest donor 
after the Global Fund, contributing an estimated 
US$41 million to harm reduction programmes, 
one-quarter of identified funding at that time. 
Since then, governments have been moving away 
from investing in harm reduction through bilateral 
programmes, with money increasingly channelled 
through multilaterals, such as the Global Fund 
and the UN. These investments are not harm 
reduction-specific but often part of wider HIV 
funding pots. Donor governments contacted as 
part of this research have, therefore, found it 
difficult to identify the extent to which the money 
they invest goes towards harm reduction. 
Despite the difficulty in isolating harm reduction 
spend, it is evident that overall funding levels 
for harm reduction have not been maintained 
through multilaterals. Although contributions to 
the Global Fund from the UK more than doubled 
between 2008-2010 and 2014-2016 from US$571 
million to US$1.26 billion,50 the increase in harm 
reduction funding through the Global Fund 
between 2007 and 2016 of US$35 million is  
less than the amount of DFID funding identified  
in 2007 (US$41 million), representing an even 
bigger reduction in real terms.
In addition, no bilateral harm reduction funding 
for AusAID has been identified in this study 
compared to 2007, when its US$16.2 million 
contribution made AusAID the third-largest donor. 
This has not only affected the overall amount 
of funding for harm reduction in LMICs, but has 
had a large impact on individual countries that 
previously benefited from bilateral support.  
For example, when AusAID finished funding  
harm reduction in Indonesia in 2015, NGOs 
providing harm reduction services to people  
who use drugs were unable to operate.[58]
50. See Global Fund pledges and contributions on the Global Fund website.
Harm reduction funding in Indonesia
Indonesia has a concentrated HIV epidemic, with HIV prevalence high among the 74,000 people 
who inject drugs in the country. Harm reduction was introduced in 2001, funded by international 
donors, several of which have continued to finance harm reduction efforts within the country. It is 
estimated that around US$18million of funding for harm reduction was provided by international 
donors in 2006 through DFID, AusAID and USAID.[8] At the time, HIV prevalence among people who 
inject drugs was estimated to be 52%. Following the expansion of harm reduction services, the 
HIV prevalence among people who inject drugs dropped to 41%, but the harm reduction response 
remained vulnerable and heavily reliant on uncertain donor support. 
When USAID completed its funding cycle in 2010, services that had been running for five years 
were forced to close. While PEPFAR continues to have a presence in Indonesia, harm reduction 
expenditure in 2016 amounted to only US$0.5 million.
The Australia Indonesia Partnership for HIV provided funding for harm reduction through AusAID 
from 2008 until 2015, when HIV prevalence was reported to have fallen to around 29%. Yet similar 
problems to 2010 were reported at its conclusion, with the closure of services previously funded 
by the donor programme. HRI country-level research found an estimated $2.7 million of harm 
reduction expenditure in 2016, comprised mostly of Global Fund monies ($2.4 million).[58] This is 
well below levels 10 years ago and despite signs that the numbers of people injecting drugs may 
have decreased, the investment is still too low to sustain an effective harm reduction response. 
There is a paucity of policy and programming that respond to the harm reduction needs of 
increasing numbers of people who use stimulants in Indonesia,[59] (a project funded by Mainline 
and operating in Jakarta in 2016 being the exception), and very little developed for women who 
use drugs.[60] With the recent change in the Global Fund Eligibility Policy,51 Indonesia will continue 
to be eligible for country allocations upon becoming an upper middle-income country, while 
there continues to be a high HIV burden among key populations. There is a need for the Global 
Fund to address these neglected areas when apportioning funding for programmes reaching 
people who use drugs in Indonesia.
Establishing the full extent of harm reduction investment by the Indonesian Government was 
not possible as data, particularly funds coming from local government, were not available. It 
is clear, however that the extent to which the government has taken financial responsibility 
for harm reduction compares poorly with that of the overall HIV response, where 57% of total 
expenditure comes from the government.[61] The only estimate of financial support available for 
2016 was a modest investment for the purchasing of methadone, enough for just 2,000 people. 
In a domestic environment that prioritises drug control and practices mandatory rehabilitation – 
US$192 million was provided through the National Anti-Narcotics Agency for narcotics prevention 
and eradication efforts in 2016[62] – harm reduction looks set to continue to be overly reliant on 
shrinking donor funds. 
Outside of PEPFAR, the Ministry of Foreign Affairs 
of the Netherlands (MoFA) stands out for its 
significant bilateral support for harm reduction. 
In 2016, it was estimated that US$4.1 million 
was spent on harm reduction, the majority of 
which (US$3.4m) was through the Bridging the 
Gaps programme, a consortium of Dutch NGOs 
and international networks working with key 
populations including people who use drugs.
The MoFA contributed US$13.8 million for the 
Community Action on Harm Reduction (CAHR)52 
programme between 2011 and 2015. Following 
the cessation of CAHR funding at the beginning  
of 2016, the MoFA continued supporting  
harm reduction through Strategic Funding  
of CAHR’s main implementation organisation, 
the International HIV/AIDS Alliance (IHAA). 
This amounted to US$294,000 in 2017, a small 
proportion of the annual funding available  
under CAHR. 
The Netherlands MoFA has also committed 
funding for harm reduction under the Partnership 
to Inspire, Transform and Connect the HIV 
response (PITCH) programme, which runs from 
2016 to 2020. It was expected that US$1.5 million 
would be spent annually on advocacy for people 
who use drugs and harm reduction, though the 
expenditure identified for this programme by 
IHAA in 2016 was considerably lower. Through the 
PITCH and Bridging the Gaps projects, the MoFA 
51. The removal of the G20 rule. 
52. Countries involved in CAHR were China, India, Indonesia, Kenya, Malaysia and later Myanmar 
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continues to provide support to harm reduction 
and human rights for people who use drugs in 
middle-income countries.
While it was possible to identify all harm reduction 
funding from donor governments, our research 
sought to document all substantial contributions. 
There may be some expenditure from wider 
programmes and those coming to an end in 
2016; for example, Norway Funds provided 
US$1.5 million of funding between May 2014 
and April 2016 under the project, ‘Strengthening 
the prevention and control of HIV/AIDS, HBV and 
HCV in Romania’. A proportion of this money 
would have been spent in 2016 on prevention 
among people who inject drugs. In addition, the 
French Government report that there may be 
some international funding for harm reduction 
through city cooperation, for example between 
Paris and Dhaka. Some funding from the German 
Government and the Swiss Government may also 
have supported harm reduction research and 
policy activities in 2016.
Harm reduction funding in Vietnam 
Injecting drug use is a key contributor to the HIV epidemic in Vietnam, with a large population 
of people who inject drugs estimated to be 226,860 in 2016. Efforts to address the epidemic 
increased in 2004 with the development of the first national HIV Strategy. Investment in HIV 
programmes and harm reduction was driven by a sizeable international donor presence, a large 
proportion of funding coming from bilateral contributions, particularly from the US Government. 
The World Bank and DFID funded a comprehensive harm reduction programme between 2003 and 
2013 consisting of NSP, condom distribution, peer outreach, drop-in centres, behavioural change, 
OST and advocacy. The Global Fund provided minimal harm reduction funding until 2009 when 
US$29.4m was allocated to the country.
The scale-up of harm reduction services such as NSP has been credited with helping to control the 
HIV epidemic among people who inject drugs.[63] Estimated NSP coverage increased substantially 
between 2006 and 2011.[64] Despite the achievements, coverage of OST remained sub-optimal, 
with a repressive political environment threatening improvements and an over-reliance on donor 
support jeopardising sustainability. In the evaluation of the World Bank/DFID programme in 2013, 
concerns were raised about the “lack of a transitional strategy to secure domestic funding for harm 
reduction interventions”.[64]
The Government of Vietnam aimed to reduce dependency on international donor support for HIV 
programmes to less than 50% by 2015 and less than 25% by 2020. However, government funding 
of the HIV programme, the National Targeted Program, under which methadone maintenance 
is provided to people who inject drugs, reportedly reduced from US$12 million in 2012 to US$4 
million in 2014.[65]  PEPFAR reduced funding over this period through a planned transition with  
a decrease in allocations from US$10.1 million in 2013 to US$1.5 million in 2016. The Global  
Fund took on some of the funding of OST after the end of the World Bank/DFID programme,  
with the Vietnamese government gradually taking on the financing of OST and due to fully-fund 
this programme in 2018. 
Vietnam is still heavily dependent on donor support for NSPs, with 90% of funding coming  
from donors in 2016, primarily the Global Fund. From 2016, after the ending of the National 
Targeted Program in 2016, the HIV programme was subsumed within a wider National Health 
Priority Programme and competes with other health priorities for funding on an annual basis. 
Questions therefore remain around whether the Vietnamese Government will provide the 
necessary financing to fund harm reduction services long-term at the level necessary to control 
the epidemic. Furthermore, despite the Vietnamese Government passing legislation that allowed 
the expansion of OST, the political environment is still restrictive. Further complicating this 
picture is the presence of, and government investment in, compulsory detention centres,  
where people who use drugs are detained and have no access to harm reduction services, 
despite evidence of improved outcomes for community-based harm reduction services 
compared to compulsory detention.[66]
2.4  Philanthropic funding for harm reduction
At US$465 million, private philanthropy accounted 
for only a small proportion (2%) of the estimated 
overall HIV spend in LMICs in 2016.[67] Notably, 
unlike donor government funding, which has 
been decreasing, philanthropic funding for HIV 
has increased for two years running.[67] However, 
very little funding for harm reduction comes from 
philanthropic donors. This study identified only 
US$6.3 million in 2016, which amounts to 1% of 
philanthropic donor funds for the HIV response 
in LMICs.[67] The majority of this was from OSF, 
primarily for advocacy work. EJAF UK and EJAF 
US also report harm reduction funding, with 
US$1.1million going to LMICs in 2016.53 
As is the case for other donors, disaggregating 
harm reduction spend is difficult for philanthropic 
organisations. A study by Funders Concerned 
about AIDS (FCAA) identified philanthropic donor 
funds for programmes for people who inject drugs 
in 2016.[67] However, much of the funding was 
not directed to LMICs54 and a significant amount 
is likely to have been ‘peripheral funding’ with 
support for programmes for key populations, 
rather than directly funding harm reduction 
services.[68] A large proportion of the harm 
reduction funding identified in the study was 
from the Bill & Melinda Gates Foundation (Gates 
Foundation). However, our communication with 
the Gates Foundation suggests that there was very 
little funding of harm reduction in 2016, with most 
HIV funding going to countries in Sub-Saharan 
Africa.[68] In 2007, US$4.8 million was identified 
from the Gates Foundation for programmes 
running in India and China, with other funding  
also identified in Russia, but this still amounted  
to a small proportion of their HIV funds overall. 
53. EJAF US funds for LMICs are focused on Mexico and the Dominican Republic, with the rest of its harm reduction funding going to the US. 
54. Half was directed towards the United States. 
Philanthropic donors contributed 
US$6.3 million for harm reduction in 
2016, just 1% of total philanthropic 
donor funding for the HIV response.
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The Gates Foundation is the largest philanthropic 
HIV donor, contributing US$680million in 2016 
globally, amounting to 35% of all HIV funding from 
philanthropic donors.[67] The Gates Foundation 
also makes a significant contribution to the Global 
Fund – totalling US$1.6 billion to date.[69] The 
Gates Foundation’s strategy, includes a focus on 
‘high-risk populations’, stating: ‘[we] concentrate 
on areas where existing funds are insufficient, 
our support can have potentially catalytic impact, 
and we can assume risks that others may not be 
able to’. The Gates Foundation is ideally placed 
to fund harm reduction. Their absence, and that 
of other large philanthropic HIV donors, is hugely 
problematic and a significant contributing factor  
to the funding crisis which must be questioned. 
Recommendations:
l  Philanthropic donors, particularly those who 
contribute large amounts for HIV funding more 
broadly, must commit more funding to harm 
reduction.
l  Philanthropic donors must leverage their access, 
position, and power as funders to call for other 
philanthropic, national and multilateral donors to 
increase their commitments to harm reduction. 
3. Domestic funding  
of harm reduction
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Determining the extent of domestic funding 
for harm reduction remains a difficult task. 
Statements of planned funding, for example, 
through policy documents such as National 
Plans, are often not followed through with 
actual investments and health spending is not 
disaggregated to the level required to identify 
investments in programmes for people who 
inject drugs.  A key data source for tracking HIV 
expenditure has been the UNAIDS National Aids 
Spending Assessment (NASA) exercises, despite 
some reservations about the accuracy of the 
information provided by national governments.[8] 
The NASA reports represent the only unified 
approach to identifying what is spent on key 
components of a country’s HIV response.  
The detail provided within the reports can vary, 
however, with some only disaggregating spend 
down to prevention rather than further identifying 
the amount that goes towards prevention for 
key populations such as people who inject drugs. 
Furthermore, these documents are no longer 
routinely made available to the public, with most 
reports on the UNAIDS website being 5 to 10 years 
old. Some further data were obtained for this 
study from UNAIDS, but there are very few recent 
data,[70] with only Ukraine having data recent 
enough to be useful for this study. 
Without this key source of information, it 
is necessary to draw upon a wide range of 
different sources and material, which are often 
contradictory and do not allow direct comparison 
across countries. These include budget plans, 
Annual Reports, individual studies, donor  
reports, funding applications, NGO reports, 
programme evaluations and key informant 
reporting. The variation in both the quality and 
quantity of the data makes it difficult to draw  
firm conclusions about the extent to which 
national governments in LMICs are funding  
their harm reduction responses.
HRI arrived at a best possible estimate of US$48.1 
million domestic investment in harm reduction 
in 2016, or nearest year.55 This equates to 26% 
of all identified harm reduction spending and 
comprised identified national investment data for 
19 countries. Domestic investment of over US$1 
million was identified in India, China, Vietnam, 
Malaysia, Kazakhstan, Georgia, Ukraine, Thailand 
and Myanmar. Table 5 contains the best available 
information on countries where there are 
estimated to be over 100,000 people who inject 
drugs. As the table shows, data sources, year of 
data and parameters differ between countries. 
Therefore, no cross-comparisons can be made and 
all data must be interpreted with caution. It is also 
of note that where harm reduction funding data 
is available, this is often not accompanied by a 
breakdown of spend by intervention, which clouds 
the extent to which government investment can 
be critically evaluated. 
Table 5: Available data, sources and uncertainties identified on domestic harm reduction investment 
in countries with over 100,000 people who inject drugs
Country Domestic 
investment 
(in US$  
millions) 
Domestic  
investment 
as a % of 
harm  
reduction 
funding
Information 
provided 
within source 
document on 
services funded
Latest UNAIDS 
national data56 
Source and  
comments
China 1.1 100% OST primarily, 
NSP not  
supported to 
same extent
None available No data  
available  
on national 
expenditure. 
Data for 2013 
for Yunnan
Russia N/A None available Municipality of 
St Petersburg 
reported to 
provide some 
support to NSP.
India 11.0 81% More  
expenditure on 
NSP than OST
2013 HRI funding 
assessment 
research 2016 
data 
Brazil57 N/A None available Indications 
of some local 
level domestic 
spend on harm 
reduction for 
crack use.
Ukraine 1.1 14% No information 
on what this 
expenditure 
covers within 
source  
document
2015 UNAIDS data 
2015 
Vietnam 10.2 41% No national 
government 
funding of NSP, 
only OST
2012 HRI funding 
assessment 
research 2016 
data
56. Some data were provided directly by UNAIDS to HRI, so not all is in the public domain.
57. It should be noted that the population size estimate for people who inject drugs in Brazil is considered an overestimate, with recent unpublished research 
suggesting very few people inject drugs in the country.  
3.  Domestic funding of harm reduction
55. Efforts were made to find data from the year 2016, but when this was unavailable, data from 2015, or 2014 were used. For Iran, it was necessary to use 
data for 2012 as no more recent data were available and Iran recorded a large amount of harm reduction spend in this year. The amount of funding 
identified for China (data was available for Yunnan province only) was for 2013.
Domestic investment in harm 
reduction was estimated to be 
US$48 million in 2016.
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Country Domestic 
investment 
(in US$  
millions) 
Domestic  
investment 
as a % of 
harm  
reduction 
funding
Information 
provided 
within source 
document on 
services funded
Latest UNAIDS 
national data  
Source and  
comments
Iran 9.9 84% No breakdown  
of funding by 
service type  
in source  
document
2012 UNAIDS data 
2012
Malaysia 5.4 95% No breakdown 
of expenditure 
but harm  
reduction  
programme  
includes both 
OST and NSP
None available Global AIDS 
Response  
Progress  
Report 2016.  
Data from 
2015.
Mexico N/A 2011 Civil society 
report a small 
amount of 
harm reduction 
funds from 
government 
through the 
national HIV 
programme.
Kazakhstan 3.6 93% Most funding 
for NSP, small 
amount for OST
2014 Figure  
represents 
planned  
funding for 
NSP and OST 
in 2016 from 
Harm  
Reduction 
Works project. 
Pakistan N/A 2013
A major gap in data on domestic investment is 
China, where an estimated 2.6 million people who 
inject drugs live and where the government is 
supporting OST and NSP provision nationwide.  
A NASA report for China was published in 2010  
but this included data from a pilot assessment in 
one province and did not cover the whole country. 
The most detailed and up-to-date estimates 
of national government expenditure on harm 
reduction have been obtained from civil society; 
for example, an HRI study tracking harm reduction 
investment in seven countries in Asia (Cambodia, 
India, Indonesia, Nepal, Philippines, Thailand  
and Vietnam).58 Using a standardised tool  
and a network of consultants within countries, 
estimating investment in key harm reduction 
interventions and identifying funding sources  
has been possible. 
Understanding the extent and size of national 
government investment in harm reduction 
is essential to assess the sustainability of the 
response and to ensure that harm reduction 
does not become even less of a priority during 
transition to national funding.  By providing 
detailed expenditure data, it is also possible  
to assess how comprehensive the harm  
reduction response is. Table 5 shows that  
some governments mainly fund OST while  
others fund mainly NSP. 
58. An HRI report and the research tools will be published 2018-19. Please contact HRI for more details. 
Figure g: Percentage of HIV spending from government alongside percentage of prevention 
spending from government
Percentage of HIV spending  
from government
Percentage of HIV prevention  
spending from government
Low income       Lower middle-income                 Upper middle-income
0
10%
20%
30%
40%
50%
60%
70%
80%
90%
 50            51         HARM REDUCTION INTERNATIONAL      The Lost Decade Methodology
Putting the findings in table 5 into perspective, 
while 10 countries spend over US$1 million on 
their national harm reduction programmes, and 
six provide the majority of harm reduction funding 
in their countries, often this is a small percentage 
of their national HIV investment. For those 
countries with identified domestic investments 
in harm reduction, on average this equated to 
less than 5% of the total (donor and government) 
HIV investment and 13% of total (donor and 
government) HIV prevention investment.59  
The only countries with national harm reduction 
investments representing over one-third of their 
HIV prevention investments were Malaysia and 
Kazakhstan. (See above case study on Kazakhstan, 
including recent threats to the OST programme.) 
While it has not been possible to come up with 
comparable estimates of national spend on harm 
reduction in this study, data from the Institute 
for Health Metrics and Evaluation[61] show that 
upper middle-income countries fund more of their 
overall HIV response than lower middle-income 
and low income countries. However, prevention60 
accounts for a lower percentage of the overall 
response in these countries.[61] 
Recommendations:
l  Governments must fund harm reduction 
programmes for people who use drugs, 
ensuring that funds effectively respond to 
the national context. Funding should include, 
but not be limited to, the UN-recommended 
package of interventions for people who use 
drugs. Governments should also support the 
development of harm reduction interventions  
for people who use stimulants.   
l  Governments must accurately track harm 
reduction allocation and expenditure in their 
countries, including via the UNAIDS NASA, to allow 
them to measure the impact of their investments 
and to inform future budget allocations. 
l  Governments must ensure civil society and people 
who use drugs remain central to the design and 
delivery of domestically-supported harm reduction 
programmes. This will require mechanisms for 
contracting NGOs and the meaningful involvement 
of people who use drugs in all aspects of policy 
and programmes. 
l  Governments should critically evaluate their 
drug control spending, its efficacy and cost-
effectiveness, with a view to shifting funds away 
from ineffective and often harmful drug law 
enforcement towards harm reduction.
This study aimed to build upon previous work 
undertaken by HRI to estimate expenditure on 
harm reduction in LMICs.[8] [10] As in the previous 
studies, there is no single source of information 
available on this topic, so the task was divided 
into two main elements; a survey of international 
donors; and estimates of national government 
expenditure.
To estimate international donor spend, a 
survey instrument was designed to collect data 
on overall harm reduction expenditure using 
2016 as the reference year and broken down 
by category of spend (health services, capacity 
building, advocacy and research). In addition, 
expenditure by recipient country was requested 
alongside contextual information on the types 
of activities funded. A list of donors was drawn 
up based on HRI’s knowledge of the funding 
landscape and suggestions from key informants 
in the harm reduction field. Surveys were sent 
via email in January 2018 to 22 donors. Further 
possible donors were identified and sent a 
survey if relevant. Information from 14 donors 
was received including nine completed survey 
responses. Other donors provided information 
via email or telephone call.  All non-respondents 
were followed-up on two or more occasions. 
Information provided by donors was checked  
with implementing organisations and key  
contacts where relevant. Where identifiable,  
harm reduction funding for high-income countries 
was excluded from the analysis. Double counting 
was considered both in the formulation of the 
survey questions and was checked for in follow-
up conversations with donors and implementing 
agencies. Particular efforts were made to ensure 
that multilateral and UN contributions from donor 
governments were only counted once. Checks 
made leave us confident that any remaining 
double-counting would be insubstantial. 
Where no response was received, efforts were 
made to check other data sources, including donor 
websites, the OECD’s International Development 
Statistics (IDS) online database and individual 
country reports. Implementing organisations and 
contacts within countries were also contacted to 
see if funding could be identified that way. This 
allowed us to be confident that any international 
donor funding not captured through our survey 
or other data gathering activities, would not 
significantly impact upon the total harm reduction 
investment figures.
Information on further harm reduction 
expenditure including national government 
expenditure was collected from a number of 
sources including UNAIDS NASA reports, budget 
plans, Annual Reports, individual studies, donor 
reports, funding applications, NGO reports, 
programme evaluations and key informant 
reporting. This was cross-referenced with country 
spend information provided by international 
donors and an overall harm reduction funding 
figure for 2016 was estimated. 
One of the primary issues with the data received 
is that for many donors and governments, 
expenditure data are not available, so the data 
reported refer to allocations and budgets rather 
than actual expenditure. Given that there are 
reports of countries not being able to spend 
funding allocations (the Global Fund estimates 
a 70% absorption rate across its portfolio), we 
can assume that the international donor spend 
represents a maximum amount. 
There were some large countries, particularly in 
South America (Brazil and Argentina) where we 
59. Calculations informed by data from TABLE B7: Health spending on HIV/AIDS, 2015 in IHME Financing Global Health 2017: Funding Universal Health 
Coverage and the Unfinished HIV/AIDS Agenda. http://www.healthdata.org/policy-report/financing-global-health-2017. Data was provided to HRI  
on a non-adjusted basis by the study author at IHME.
60. Currently, IHME prevention estimates include prevention of mother-to-child transmission (PMTCT). IHME hope to separate these out in future.
Methodology
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were unable to find much national spend data 
on harm reduction funding. We cross-checked 
with the responses from the Global State of Harm 
Reduction 2018 data-gathering exercise and key 
country informants to assess the impact of this. 
In most cases, there appeared to be little funding 
going towards harm reduction services in these 
countries. An important exception to this is China, 
where funding data was outdated and limited to 
Yunnan province, but where we know there are 
extensive harm reduction programmes supported 
by the Chinese government.   
Analysis of the data was carried out in Excel. 
Countries were grouped by income status using 
the FY2016 World Bank classification. Russia was 
included in the analysis despite being classified as 
a high income country in 2016 as this classification 
occurred for only a short period of time and 
the funding of harm reduction services is a key 
concern in Russia given the size of the population 
who inject drugs. 
Where trends in expenditure/funding are 
presented, these have been adjusted to 2016 
prices using the US Bureau of Labor Statistics  
CPI data for January of each year.61 
Data on harm reduction investments from  
the Global Fund are for allocations rather  
than expenditure. In the previous rounds-based 
funding cycles, allocations were spread over  
a number of years, which makes analysis of  
trends difficult. In order to adjust for this and 
attempt to come to figures more likely to 
represent actual year-on-year changes in harm 
reduction funding, we undertook a re-analysis of 
the figures in Bridge et al. (2016). This involved 
going back to the original spreadsheets for 
each individual round and extracting the data 
on funding for each component (e.g. NSP, OST) 
by year (i.e. year 1, year 2 etc.). It was assumed 
that year 1 for each grant was the year after the 
allocation, so for 2008, year 1 was labelled as 
2009, year 2 as 2010 and so on. A random grant 
was chosen from each funding round to check  
this assumption by looking at the start date and 
apart from the initial rounds in 2002 and 2003, 
this appeared to be a valid assumption. Data for 
each funding round were therefore labelled this 
way and consolidated into a worksheet containing 
funding data by individual year.
Unfortunately 2014-2016 data from the new 
grants following the change to the allocation 
funding model were not provided in sufficient 
detail to enable this adjustment to be made  
for those years. It is recommended that the  
Global Fund provides data on disbursements  
or expenditure so that trends in funding levels  
can be assessed accurately.
61. Available online here: https://www.bls.gov/cpi/tables/supplemental-files/historical-cpi-u-201805.pdf
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